<SEC-DOCUMENT>0001193125-24-201366.txt : 20240815
<SEC-HEADER>0001193125-24-201366.hdr.sgml : 20240815
<ACCEPTANCE-DATETIME>20240815164611
ACCESSION NUMBER:		0001193125-24-201366
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20240815
DATE AS OF CHANGE:		20240815

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nuvation Bio Inc.
		CENTRAL INDEX KEY:			0001811063
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				850862255
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-281255
		FILM NUMBER:		241213101

	BUSINESS ADDRESS:	
		STREET 1:		357 TEHAMA STREET, FLOOR 3
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94103
		BUSINESS PHONE:		(415) 754-3517

	MAIL ADDRESS:	
		STREET 1:		357 TEHAMA STREET, FLOOR 3
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Panacea Acquisition Corp
		DATE OF NAME CHANGE:	20200430
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d881368d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3) <BR>Registration No. 333-281255 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g881368g00q03.jpg" ALT="LOGO" STYLE="width:1.79167in;height:0.572917in;">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>Up to 115,660,186 Shares of Class&nbsp;A Common Stock Offered by the Selling Securityholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>Up to 2,893,731 Shares of Class&nbsp;A Common Stock Issuable Upon Exercise of Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>Up to 2,893,731 Warrants to Purchase Class&nbsp;A Common Stock Offered by the Selling Securityholders </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to the issuance by us of up to 2,893,731 shares of our Class&nbsp;A common stock, $0.0001 par value per share (the
&#147;common stock&#148;) that are issuable upon the exercise of warrants at an exercise price of $11.50 per share (the &#147;warrants&#148;) issued in connection with the acquisition (the &#147;Acquisition&#148;) of AnHeart Therapeutics, Ltd.
(&#147;AnHeart&#148;), pursuant to that certain Agreement and Plan of Merger (the &#147;Merger Agreement&#148;), dated March&nbsp;24, 2024, by and among Nuvation Bio Inc. (the &#147;Company&#148;), AnHeart, Artemis Merger Sub I, Ltd., a wholly owned
subsidiary of the Company, and Artemis Merger Sub II, Ltd., a wholly owned subsidiary of the Company (the &#147;Merger Warrants&#148;). We will receive the proceeds from the exercise of any Merger Warrants for cash. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus also relates to the proposed resale or other disposition from time to time by the selling securityholders named in this
prospectus or their permitted transferees (the &#147;selling securityholders&#148;) of an aggregate of (i)&nbsp;up to 115,660,186 shares of common stock consisting of (a)&nbsp;up to 27,646,255 shares of common stock issued pursuant to the Merger
Agreement (the &#147;Merger Common Shares&#148;), (b) up to 85,120,200 shares of common stock (the &#147;Merger Conversion Shares&#148;) that are issuable upon the conversion of 851,202 shares (the &#147;Merger Preferred Shares&#148;) of our Series
A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Convertible Preferred Stock (the &#147;preferred stock&#148;) issued pursuant to the Merger Agreement, and (c)&nbsp;up to 2,893,731 shares of common stock that are issuable upon the exercise of
the Merger Warrants, and (ii)&nbsp;up to 2,893,731 Merger Warrants. We will not receive any proceeds from the sale of shares of common stock or Merger Warrants by the selling securityholders pursuant to this prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling securityholders may offer, sell or distribute all or a portion of the securities hereby registered publicly or through private
transactions at prevailing market prices or at negotiated prices. We will not receive any of the proceeds from such sales of the shares of common stock or Merger Warrants, except with respect to amounts received by us upon exercise of the Merger
Warrants, up to an aggregate of approximately $33.3&nbsp;million assuming the exercise in full of all of the Merger Warrants for cash. We will bear all costs, expenses and fees in connection with the registration of these securities, including with
regard to compliance with state securities or &#147;blue sky&#148; laws. The selling securityholders will bear all commissions and discounts, if any, attributable to their sale of shares of common stock or Merger Warrants. See the section titled
&#147;<I>Plan of Distribution</I>.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock and Merger Warrants are listed on the New York Stock Exchange
(&#147;NYSE&#148;)<B></B>&nbsp;under the symbols &#147;NUVB&#148; and &#147;NUVB.WS,&#148; respectively. On August&nbsp;14, 2024, the last reported sales price of our common stock was $2.74 per share and the last reported sales price of our Merger
Warrants was $0.14 per warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a &#147;smaller reporting company&#148; as defined under the U.S. federal securities laws. See
&#147;Prospectus Summary &#151; Implications of Being a Smaller Reporting Company.&#148; This prospectus complies with the requirements that apply to an issuer that is a smaller reporting company. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities involves a high degree of risks. You should review carefully the risks and uncertainties described in the
section titled &#147;<A HREF="#toc881368_5">Risk&nbsp;Factors</A>&#148; on page&nbsp;8 of this prospectus, and under similar headings in any amendments or supplements to this prospectus and the documents incorporated herein by reference. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or
passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus
dated August&nbsp;15, 2024 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc881368_1">About this Prospectus</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc881368_2">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc881368_3">Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc881368_4">The Offering</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc881368_5">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc881368_6">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc881368_7">Selling Securityholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc881368_8">Plan of Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc881368_9">Description of Securities </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc881368_10">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc881368_11">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc881368_12">Where you can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc881368_13">Incorporation of Certain Information by Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No person is authorized to give any information or to make any representation that is different from, or in addition to, those contained or
incorporated by reference into this prospectus supplement or the accompanying prospectus and, if given or made, such information or representations must not be relied upon as having been authorized. Neither we nor the selling securityholders have
authorized anyone to provide you with additional information or information different from that contained in this prospectus filed with the Securities and Exchange Commission (&#147;SEC&#148;). We take no responsibility for, and can provide no
assurance as to the reliability of, any other information that others may give you. The selling securityholders are offering to sell, and seeking offers to buy, our securities only in jurisdictions where offers and sales are permitted. The
information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of our securities. Our business, financial condition, results of operations and prospects
may have changed since that date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For investors outside of the United States: Neither we nor the selling securityholders, have done
anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of
this prospectus must inform themselves about, and observe any restrictions relating to, the offering of our securities and the distribution of this prospectus outside the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent there is a conflict between the information contained in this prospectus, on the one hand, and the information contained in any
document incorporated by reference filed with the SEC before the date of this prospectus, on the other hand, you should rely on the information in this prospectus. If any statement in a document incorporated by reference is inconsistent with a
statement in another document incorporated by reference having a later date, the statement in the document having the later date modifies or supersedes the earlier statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc881368_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we filed with the SEC using the &#147;shelf&#148; registration process. Under this
shelf registration process, the selling securityholders may, from time to time, sell the securities offered by them described in this prospectus. We will not receive any proceeds from the sale by such selling securityholders of the securities
offered by them described in this prospectus. This prospectus also relates to the issuance by us of the shares of common stock issuable upon the exercise of any warrants. We will not receive any proceeds from the sale of shares of common stock
underlying the warrants pursuant to this prospectus, except with respect to amounts received by us upon the exercise of the Private Warrants for cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor the selling securityholders have authorized anyone to provide you with any information or to make any representations other
than those contained in or incorporated by reference into this prospectus or any applicable prospectus supplement prepared by or on behalf of us or to which we have referred you. Neither we nor the selling securityholders take responsibility for,
and can provide no assurance as to the reliability of, any other information that others may give you. Neither we nor the selling securityholders will make an offer to sell these securities in any jurisdiction where the offer or sale is not
permitted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also provide a prospectus supplement or post-effective amendment to the registration statement to add information to,
or update or change information contained in, this prospectus. You should read both this prospectus and any applicable prospectus supplement or post-effective amendment to the registration statement together with the additional information to which
we refer you in the section of this prospectus titled &#147;<I>Where You Can Find More Information</I>&#148; and &#147;<I>Incorporation by Reference</I>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should assume that the information appearing in this prospectus and the applicable prospectus supplement to this prospectus is accurate
only as of the date on its respective cover and that any information incorporated by reference is accurate only as of the date of the document incorporated by reference, unless we indicate otherwise. Our business, financial condition, results of
operations and prospects may have changed since those dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context indicates otherwise, references in this prospectus to the
&#147;Company,&#148; &#147;Nuvation Bio,&#148; &#147;we,&#148; &#147;us,&#148; &#147;our&#148; and similar terms refer to Nuvation Bio Inc. and its consolidated subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc881368_2"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and the documents incorporated by reference herein and any prospectus supplement delivered with this prospectus may contain
forward-looking statements that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terms such as &#147;anticipate,&#148; &#147;believe,&#148; &#147;continue,&#148; &#147;could,&#148;
&#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;might,&#148; &#147;objective,&#148; &#147;ongoing,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;should,&#148;
&#147;will&#148; and &#147;would,&#148; or the negative of these terms or other similar expressions intended to identify statements about the future. These statements speak only as of the date such forward-looking statement is made and involve known
and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking
statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These
forward-looking statements include, without limitation, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to recognize the anticipated benefits of the Acquisition, which may be affected by, among other
things, competition and our ability to grow and manage growth profitably; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans to develop and commercialize our product candidates, including our expectations regarding a New Drug
Application in the United States; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, timing, progress and results of our current and future preclinical studies and clinical trials,
as well as our research and development programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> additional product
candidates on reasonable terms; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain and establish collaborations or obtain additional funding; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain regulatory approval of our current and future product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the potential market size and the rate and degree of market acceptance of such product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our continued reliance on third parties to conduct clinical trials of our product candidates, and for the
manufacture of our product candidates for preclinical studies and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to fund our working capital requirements and expectations regarding the sufficiency of our capital
resources; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the implementation of our business model and strategic plans for our business and product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our intellectual property position and the duration of our patent rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments or disputes concerning our intellectual property or other proprietary rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding government and third-party payor coverage and reimbursement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to compete in the markets we serve; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of government laws and regulations and liabilities thereunder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our need to hire additional personnel and our ability to attract and retain such personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to raise additional funding in the future; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the anticipated use of our cash and cash equivalents. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing list of forward-looking statements is not exhaustive. Because forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted or quantified and some of which </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
are beyond our control, you should not rely on these forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking
statement contained in this prospectus or any documents incorporated by reference herein and any prospectus supplement, the events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could
differ materially from those projected in the forward-looking statements. You should refer to the section titled &#145;&#145;Risk Factors&#146;&#146; in this prospectus for a discussion of important factors that may cause our actual results to
differ materially from those expressed or implied by our forward-looking statements. Other sections of this prospectus may include additional factors that could harm our business and financial performance. Moreover, we operate in an evolving
environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. As a result of these factors, we cannot assure you that the forward-looking statements
in this prospectus or any documents incorporated by reference herein and an prospectus supplement will prove to be accurate. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained
herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You
should read this prospectus, any documents incorporated by reference herein and the documents that we reference in this prospectus and have filed as exhibits to the registration statement, of which this prospectus is a part, completely and with the
understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. In addition, statements that &#147;we believe&#148; and similar statements
reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus and while we believe such information forms a reasonable basis for such statements, such
information may be limited or incomplete, and such statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain
and investors are cautioned not to unduly rely upon these statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc881368_3"></A>SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary does not contain all of the information that you should consider in making your investment decision. Before investing in our
securities, you should carefully read this entire prospectus, including our consolidated financial statements, the related notes thereto and the information set forth in the section titled &#147;Risk Factors&#148; and other information incorporated
by reference from our other filings with the SEC. Unless the context otherwise requires, we use the terms &#147;Nuvation Bio,&#148; &#147;company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; in this prospectus to refer to Nuvation Bio
Inc. and our wholly owned subsidiaries. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing
differentiated and novel product candidates. We were founded in 2018 by our chief executive officer, David Hung, M.D., who founded Medivation, Inc. and led its successful development of oncology drugs Xtandi<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and talazoparib (now marketed as Talzenna<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>), leading to its $14.3&nbsp;billion sale to Pfizer Inc. in 2016. We leverage our team&#146;s
extensive expertise in medicinal chemistry, preclinical development, drug development, business development, manufacturing, and commercialization to pursue oncology targets validated by strong clinical or preclinical data and develop novel small
molecules that improve the activity and overcome the liabilities of currently marketed drugs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of the Acquisition, our most
advanced clinical stage product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation ROS1 inhibitor specifically designed for the treatment of patients with advanced ROS1-positive <FONT
STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (&#147;NSCLC&#148;). Taletrectinib is being evaluated for the treatment of patients with advanced ROS1-positive NSCLC in two Phase 2 <FONT STYLE="white-space:nowrap">single-arm</FONT>
pivotal studies: <FONT STYLE="white-space:nowrap">TRUST-I</FONT> in China, and <FONT STYLE="white-space:nowrap">TRUST-II,</FONT> a global study. Taletrectinib has been granted Orphan Drug Designation by the U.S. Food and Drug Administration
(&#147;FDA&#148;) for the treatment of patients with ROS1-positive NSCLC and other NSCLC indications, and Breakthrough Therapy Designations by both the FDA and China&#146;s National Medical Products Administration (&#147;NMPA&#148;) for the
treatment of patients with advanced or metastatic ROS1-positive NSCLC. Based on results of the <FONT STYLE="white-space:nowrap">TRUST-I</FONT> clinical study, China&#146;s NMPA has accepted and granted Priority Review Designations to New Drug
Applications for taletrectinib for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC who either have or have not previously been treated with ROS1 tyrosine kinase inhibitors. Worldwide development and commercial
rights to taletrectinib have been <FONT STYLE="white-space:nowrap">in-licensed</FONT> from Daiichi Sankyo. Commercial rights to taletrectinib have been <FONT STYLE="white-space:nowrap">out-licensed</FONT> in China and Japan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to taletrectinib, our pipeline includes differentiated, novel oncology therapeutic candidates that have been generated from our
proprietary drug discovery and development programs or acquired through business development activities: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Safusidenib, a novel, oral, potent, targeted inhibitor of mutant isocitrate dehydrogenase 1 (&#147;IDH1&#148;),
which is being evaluated in a global Phase 2 study for the treatment of patients with diffuse IDH1-mutant glioma; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">NUV-1511,</FONT> our first clinical-stage drug-drug conjugate, which is being
evaluated in a Phase 1/2 study for the treatment of patients with advanced solid tumors who previously received and progressed on or after treatment with Enhertu<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and/or Trodelvy<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> per approved U.S. FDA labeling, human epidermal growth factor receptor <FONT STYLE="white-space:nowrap">2-negative</FONT> metastatic breast cancer, metastatic castration-resistant prostate
cancer, advanced pancreatic cancer, and platinum-resistant ovarian cancer; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">NUV-868,</FONT> a <FONT STYLE="white-space:nowrap">BD2-selective,</FONT> oral,
small molecule bromodomain and extra-terminal inhibitor that inhibits BRD4, which has completed Phase 1 monotherapy and Phase 1b combination studies. We have decided not to initiate a Phase 2 study of NUV-868 as a monotherapy or in combination with
olaparib </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
or enzalutamide in the advanced solid tumor indications that were part of the Phase 1 and Phase 1b study designs. We are currently evaluating next steps for the
<FONT STYLE="white-space:nowrap">NUV-868</FONT> program, including further development in combination with approved products for indications in which <FONT STYLE="white-space:nowrap">BD2-selective</FONT> BET inhibitors may improve outcomes for
patients. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have no revenue to date and we have incurred net losses of $75.8&nbsp;million and $104.2&nbsp;million for
the years ended December&nbsp;31, 2023 and 2022, respectively, and an accumulated deficit of $361.2&nbsp;million from inception through March&nbsp;31, 2024. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Acquisition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;9, 2024,
the Company completed the Acquisition of AnHeart. Pursuant to the terms of the Merger Agreement, the Company issued to AnHeart securityholders approximately (i) 27,646,255 Merger Common Shares, (ii) 851,202 Merger Preferred Shares, and (iii)
2,893,731 Merger Warrants. The Merger Preferred Shares are automatically convertible into an aggregate of approximately 85,120,200 Merger Conversion Shares upon the approval of such conversion by the Company&#146;s stockholders in accordance with
the rules of the New York Stock Exchange. The Merger Warrants are restricted with respect to the exercise and transfer thereof until receipt of such stockholder approval and otherwise have terms identical to those of the Company&#146;s outstanding
publicly traded warrants. We have filed a proxy statement with the SEC to solicit such stockholder approval, among other matters, at our 2024 Annual Meeting of Stockholders scheduled to be held on September&nbsp;3, 2024. Except as otherwise required
by law (e.g. voting on a change to the authorized shares of preferred stock or the rights of such shares as required by Delaware General Corporation Law) and the Company&#146;s Certificate of Designation of Series A
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Convertible Preferred Stock (the &#147;Certificate of Designation&#148;), the preferred stock does not have voting rights. For more information on the preferred stock, please refer to the
Certificate of Designation, which is filed as an exhibit to the registration statement of which this prospectus is a part and incorporated by reference herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of immediately following the consummation of the Acquisition, the securityholders of AnHeart immediately prior to the Merger now own
approximately <FONT STYLE="white-space:nowrap">one-third</FONT> of Nuvation Bio&#146;s capital stock (including shares issuable with respect to assumed options and assumed restricted stock units), and the securityholders of Nuvation Bio immediately
prior to the Merger now own approximately <FONT STYLE="white-space:nowrap">two-thirds</FONT> of Nuvation Bio&#146;s capital stock, in each case determined on a fully-diluted basis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were
incorporated in Delaware in April 2020 as a blank check company under the name Panacea Acquisition Corp. (&#147;Panacea&#148;). On February&nbsp;10, 2021 (the &#147;Panacea Merger Closing Date&#148;), Nuvation Bio Operating Company Inc., formerly
Nuvation Bio Inc. (&#147;Legacy Nuvation Bio&#148;), Panacea and Panacea Merger Subsidiary Corp. (&#147;Merger Sub&#148;) consummated the closing of the transactions contemplated by an Agreement and Plan of Merger among them dated October&nbsp;20,
2020 (the &#147;Panacea Merger Agreement&#148;). Pursuant to the terms of the Panacea Merger Agreement, a combination of Legacy Nuvation Bio and Panacea was effected through the merger of Merger Sub with and into Legacy Nuvation Bio, with Legacy
Nuvation Bio surviving as a wholly owned subsidiary of Panacea. On the Panacea Merger Closing Date, Legacy Nuvation Bio changed its name to Nuvation Bio Operating Company Inc. and Panacea changed its name to Nuvation Bio Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive office is located at 1500 Broadway, Suite 1401, New York, New York 10036, where we lease approximately 7,900 square
feet of office space under a lease that terminates in 2027. We also occupy approximately 25,139 square feet of office space in San Francisco, California, under a lease that terminates in 2025 and a total of approximately 1,582 square meters of
office space in the People&#146;s Republic of China, in the cities of Beijing, Guangzhou, Hangzhou, Shanghai and Yantai, under leases that terminate in 2024 through 2026. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
We believe that these existing facilities will be adequate for our current needs and that suitable additional or alternative space will be available in the future on commercially reasonable
terms, if required. Our telephone number is (332) <FONT STYLE="white-space:nowrap">208-6102.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Nuvation Bio&#148; and our
other registered and common law trade names, trademarks and service marks are property of Nuvation Bio Inc. This prospectus contains additional trade names, trademarks and service marks of others, which are the property of their respective owners.
Solely for convenience, trademarks and trade names referred to in this prospectus may appear without the <SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> or <SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> symbols. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being a Smaller Reporting Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a smaller reporting company as defined in the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;). In our 2023
Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> which is incorporated by reference into this prospectus, we have taken advantage of certain of the scaled disclosures available to smaller reporting companies. Specifically, as a
smaller reporting company, we have chosen to present only the two most recent fiscal years of audited financial statements in our 2023 Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and to comply with reduced disclosure
obligations regarding executive compensation. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc881368_4"></A>THE OFFERING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Issuance of common stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of common stock offered by us </P></TD>
<TD>Up to 2,893,731 shares of our common stock that are issuable upon the exercise of Merger Warrants. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of common stock outstanding prior to exercise of Merger Warrants </P></TD>
<TD>248,245,129 shares (as of July&nbsp;31, 2024) </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of common stock outstanding assuming exercise of all Merger Warrants </P></TD>
<TD>251,138,860 shares (based on total shares outstanding on July&nbsp;31, 2024) </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Exercise price of warrants </P></TD>
<TD>$11.50 per share, subject to adjustment as described herein. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We will receive up to an aggregate of approximately $33.3&nbsp;million from the exercise of all of the Merger Warrants, assuming the exercise in full of all of the Merger Warrants for cash. We expect to use the net proceeds from the exercise of
the Merger Warrants for general corporate purposes. See the section titled &#147;<I>Use of Proceeds.&#148; </I></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Resale of common stock and warrants </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of common stock offered by the selling securityholders </P></TD>
<TD>We are registering the resale by the selling securityholders named in this prospectus, or their permitted transferees, of an aggregate of up to 115,660,186 shares of common stock, consisting of: </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="40%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">up to 27,646,255 Merger Common Shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="40%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">up to 85,120,200 Merger Conversion Shares; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="40%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">up to 2,893,731 shares of common stock issuable upon the exercise of the Merger Warrants. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Warrants offered by the selling securityholders </P></TD>
<TD>Up to 2,893,731 Merger Warrants </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We will not receive any of the proceeds from the sale of the shares of common stock or warrants by the selling securityholders. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>Before investing in our securities, you should carefully read and consider the information set forth in the section titled &#147;<I>Risk Factors</I>&#148; on page&nbsp;8 of this prospectus. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">NYSE ticker symbols </P></TD>
<TD>Our common stock and warrants are listed on the NYSE under &#147;NUVB&#148; and &#147;NUVB.WS&#148;, respectively. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For additional
information concerning the offering, see the section titled &#147;<I>Plan of Distribution</I>&#148; beginning on page 14 of this prospectus. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc881368_5"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our securities involves a high degree of risk. Before you make a decision to buy our securities, in addition to the risks and
uncertainties discussed in the section titled &#147;Special Note Regarding Forward-Looking Statements,&#148; you should carefully consider the risks and uncertainties incorporated by reference to our most recent Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K,</FONT> any subsequent Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> or Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> and all other information contained or incorporated
by reference into this prospectus, as updated by our subsequent filings under the Exchange Act, and the risk factors and other information contained in any applicable prospectus supplement before acquiring any of such securities. Additional risks
and uncertainties not presently known to us or that we currently believe to be immaterial may become material and adversely affect our business. The occurrence of any of these risks might cause you to lose all or part of your investment in the
offered securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc881368_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will not receive any proceeds from the sale of securities by the selling securityholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will receive up to an aggregate of approximately $33.3&nbsp;million from the exercise of the Merger Warrants, assuming the exercise in full
of all of the Merger Warrants for cash. We expect to use the net proceeds from the exercise of the Merger Warrants for general corporate purposes. We will have broad discretion over the use of proceeds from the exercise of the Merger Warrants. There
is no assurance that the holders of the Merger Warrants will elect to exercise any or all of such Merger Warrants. To the extent that the Merger Warrants are exercised on a &#147;cashless basis,&#148; the amount of cash we would receive from the
exercise of the Merger Warrants will decrease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc881368_7"></A>SELLING SECURITYHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to the resale by the selling securityholders from time to time of (i)&nbsp;up to 115,660,186 shares of common stock
consisting of (a)&nbsp;up to 27,646,255 Merger Common Shares, (b)&nbsp;up to 85,120,200 Merger Conversion Shares, and (c)&nbsp;up to 2,893,731 shares of common stock that are issuable upon the exercise of the Merger Warrants, and (ii)&nbsp;up to
2,893,731 Merger Warrants. The selling securityholders may from time to time offer and sell any or all of the common stock and Merger Warrants set forth below pursuant to this prospectus and any accompanying prospectus supplement. As used in this
prospectus, the term &#147;selling securityholders&#148; includes the persons listed in the table below, together with any additional selling securityholders listed in a subsequent amendment to this prospectus, and their pledgees, donees,
transferees, assignees, successors, designees and others who later come to hold any of the selling securityholders&#146; interests in the common stock or Merger Warrants, other than through a public sale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as set forth in the footnotes below, the following table sets forth, based on written representations from the selling securityholders,
certain information as of July&nbsp;31, 2024 regarding the beneficial ownership of our common stock and Merger Warrants by the selling securityholders and the shares of common stock and Merger Warrants being offered by the selling securityholders.
The number of shares set forth below assumes the conversion of one Merger Preferred Share into 100 Merger Conversion Shares pursuant to the Certificate of Designation. The applicable percentage ownership of common stock is based on approximately
248,245,129 shares of common stock and 1,000,000 shares of our Class&nbsp;B common stock, $0.0001 par value per share, outstanding as of July&nbsp;31, 2024, and, for each selling securityholder, assumes the conversion of only the preferred stock
owned by such selling securityholder but not the preferred stock owned by any other selling securityholder. Information with respect to shares of common stock and Merger Warrants owned beneficially after the offering assumes the sale of all of the
shares of common stock or Merger Warrants registered hereby. The selling securityholders may offer and sell some, all or none of their shares of common stock or Merger Warrants, as applicable, provided that the Merger Preferred Shares may only be
offered after such Merger Preferred Shares are converted to Merger Conversion Shares pursuant to the terms of the Certificate of Designation, and provided further that the Merger Warrants may not be transferred or exercised prior to Stockholder
Approval (as defined in the Certificate of Designation). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have determined beneficial ownership in accordance with the rules of the SEC.
Except as indicated by the footnotes below, we believe, based on the information furnished to us, that the selling securityholders have sole voting and investment power with respect to all shares of common stock and Merger Warrants that they
beneficially own, subject to applicable community property laws. Except as otherwise described below, based on the information provided to us by the selling securityholders, no selling securityholder is a broker-dealer or an affiliate of a broker
dealer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise disclosed herein, the selling securityholders do not have, and within the past three years have not had, any
position, office or other material relationship with us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please see the section titled &#147;<I>Plan of Distribution</I>&#148; in this prospectus for
further information regarding the selling securityholder&#146;s method of distributing these shares. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares of Class&nbsp;A Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Warrants to Purchase Class&nbsp;A Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>Beneficially<BR>Owned<BR>Prior&nbsp;to<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>Registered<BR>for&nbsp;Sale<BR>Hereby</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>Beneficially<BR>Owned<BR>After<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent<BR>Owned<BR>After<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>Beneficially<BR>Owned<BR>Prior to<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>Registered<BR>For Sale<BR>Hereby</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>Beneficially<BR>Owner<BR>After<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent<BR>Owner<BR>After<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Bing Yan<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,268,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,200,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,068,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cenova China Healthcare Fund V,
L.P.<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,322,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,322,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">208,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">208,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Decheng Anbio Limited<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,500,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,500,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">437,834</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">437,834</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Decheng Capital China Life Sciences USD Fund III,<BR>L.P.<SUP
STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,314,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,314,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,877</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,877</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Decheng Capital Global Healthcare Fund (Master),
LP<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,786,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,008,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">777,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">175,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">175,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Hangzhou Dejia Chengyu Investment Partnership (Limited Partnership)<SUP
STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,379,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,379,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">284,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">284,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Hangzhou Fulin Venture Capital Partnership (Limited Partnership)<SUP
STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">876,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">876,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Hangzhou Heda New Pharmaceutical Venture Capital Partnership (Limited Partnership)<SUP
STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,745,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,745,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Jiaxing Liding Chengyu Equity Investment Partnership (Limited Partnership)<SUP
STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,031,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,031,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Junyuan Jerry Wang<SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,188,133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,760,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,427,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Laurion Capital Master Fund Ltd.<SUP STYLE="font-size:75%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,658,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,658,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">166,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">166,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Lihua Zheng<SUP STYLE="font-size:75%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,547,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,559,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">988,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64,046</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64,046</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Ocean Ridge Partners Ltd.<SUP STYLE="font-size:75%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">540,941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">540,941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Octagon Investments Master Fund
LP<SUP STYLE="font-size:75%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,161,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,161,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">104,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">104,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Octagon Private Opportunities Fund
LP<SUP STYLE="font-size:75%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,161,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,161,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">104,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">104,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Octagon Special Opportunities Fund
LP<SUP STYLE="font-size:75%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,161,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,161,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">104,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">104,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Protegolumos Ltd<SUP STYLE="font-size:75%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">166,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">166,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Repulse Bay Associate Corp.<SUP STYLE="font-size:75%; vertical-align:top">(14)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">229,635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">229,635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Sage Partners Master Fund<SUP STYLE="font-size:75%; vertical-align:top">(15)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,658,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,658,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">166,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">166,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Sungsheung International Ltd.<SUP STYLE="font-size:75%; vertical-align:top">(16)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,080,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,080,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Vertex Ventures IV, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(17)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,594,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,594,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">139,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">139,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">WangWang LLC<SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,304,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,304,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Zhaoyingtong Limited<SUP STYLE="font-size:75%; vertical-align:top">(18)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,549,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,549,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">364,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">364,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>*</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Less than 1% </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Interests include (i) 765,003 shares of common stock, (ii) 2,355,400 shares of common stock issuable upon
conversion of the Merger Conversion Shares, (iii) 80,072 shares of common stock issuable upon exercise of the Merger Warrants, (iv)&nbsp;193,059 restricted stock units, and (v) 874,968 options exercisable within 60 days of July&nbsp;31, 2024.
Mr.&nbsp;Yan serves </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
as president of the Company&#146;s China AnHeart division. The principal business address for the person named in this footnote is c/o Nuvation Bio Inc., 1500 Broadway, Suite 1401, New York, NY
10036. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Interests include (i) 1,989,342 shares of common stock, (ii) 6,125,000 shares of common stock issuable upon
conversion of the Merger Conversion Shares, and (iii) 208,224 shares of common stock issuable upon exercise of the Merger Warrants. The principal business address for the entity named in this footnote is 55 Gaoyou Road, Xuhui District, Shanghai
City, China. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Interests include (a) (i) 4,183,002 shares of common stock, (ii) 12,879,200 shares of common stock issuable upon
conversion of the Merger Conversion Shares, and (iii) 437,834 shares of common stock issuable upon exercise of the Merger Warrants held by Decheng Anbio Limited (&#147;SPV&#148;); (b) (i) 314,106 shares of common stock, (ii) 967,100 shares of common
stock issuable upon conversion of the Merger Conversion Shares, and (iii) 32,877 shares of common stock issuable upon exercise of the Merger Warrants held by Decheng Capital China Life Sciences USD Fund III, L.P. (&#147;Fund III&#148;); and (c) (i)
2,453,131 shares of common stock, (ii) 5,157,900 shares of common stock issuable upon conversion of the Merger Conversion Shares, and (iii) 175,346 shares of common stock issuable upon exercise of the Merger Warrants held by Decheng Capital Global
Healthcare Fund (Master), LP (&#147;Healthcare&#148;). These securities are owned directly by Fund III, Healthcare and SPV. Dr.&nbsp;Min Cui is (i)&nbsp;the manager of Decheng Capital Management III (Cayman), LLC, the general partner of Fund III,
(ii)&nbsp;the indirect managing member and ultimate beneficial owner of Decheng Capital Global Healthcare GP, LLC, the general partner of Healthcare, and (iii)&nbsp;a director of SPV. The principal business address for each person and entity named
in this footnote is No.&nbsp;6, 1006 Huashan Road, Shanghai 200050, China. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Interests include (i) 2,720,001 shares of common stock, (ii) 8,374,700 shares of common stock issuable upon
conversion of the Merger Conversion Shares, and (iii) 284,702 shares of common stock issuable upon exercise of the Merger Warrants. The principal business address for the entity named in this footnote is No.&nbsp;6, 1006 Huashan Road, Shanghai
200050, China. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Interests include (i) 209,423 shares of common stock, (ii) 644,800 shares of common stock issuable upon
conversion of the Merger Conversion Shares, and (iii) 21,902 shares of common stock issuable upon exercise of the Merger Warrants. The principal business address for the entity named in this footnote is Floor 14, Chuangxin Building, 3850 Jiangnan
Avenue, Binjiang District, Hangzhou City, Zhejiang Province, China. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Interests include (i) 895,204 shares of common stock, (ii) 2,756,200 shares of common stock issuable upon
conversion of the Merger Conversion Shares, and (iii) 93,700 shares of common stock issuable upon exercise of the Merger Warrants. The principal business address for the entity named in this footnote is Floor 10, Building A, Hupan Center, Qiantang
District, Hangzhou City, Zhejiang Province, China. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Interests include (i) 1,202,740 shares of common stock, (ii) 3,703,100 shares of common stock issuable upon
conversion of the Merger Conversion Shares, and (iii) 125,890 shares of common stock issuable upon exercise of the Merger Warrants. The principal business address for the entity named in this footnote is Floor 49, Wandu Center, 8 Xingyi Road,
Changning District, Shanghai City, China. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Interests include (a) (i) 826,137 shares of common stock, (ii) 2,543,600 shares of common stock issuable upon
conversion of the Merger Conversion Shares, (iii) 86,471 shares of common stock issuable upon exercise of the Merger Warrants, (iv) 552,852 restricted stock units, and (v) 874,968 options exercisable within 60 days of July&nbsp;31, 2024 held by
Dr.&nbsp;Wang; and (b) (i) 550,758 shares of common stock, (ii) 1,695,700 shares of common stock issuable upon conversion of the Merger Conversion Shares, and (iii) 57,647 shares of common stock issuable upon exercise of the Merger Warrants held by
WangWang LLC. These securities are owned directly by Dr.&nbsp;Wang and WangWang, LLC, of which Dr.&nbsp;Wang is Manager. Dr.&nbsp;Wang is a member of the Company&#146;s board of directors and is chief executive officer of AnHeart Therapeutics. The
principal business address for each person and entity named in this footnote is c/o Nuvation Bio Inc., 1500 Broadway, Suite 1401, New York, NY 10036. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Interests include (i) 1,591,475 shares of common stock, (ii) 4,900,000 shares of common stock issuable upon
conversion of the Merger Conversion Shares, and (iii) 166,579 shares of common stock issuable upon exercise of the Merger Warrants. The principal business address for the entity named in this footnote is c/o Laurion Capital Management LP, 360
Madison Avenue, Suite 1900, New York, NY 10017. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Interests include (i) 1,053,066 shares of common stock, (ii) 1,883,900 shares of common stock issuable upon
conversion of the Merger Conversion Shares, (iii) 64,046 shares of common stock issuable upon exercise of the Merger Warrants, (iv) 113,150 restricted stock units, and (v) 433,794 options exercisable within 60 days of July&nbsp;31, 2024.
Mr.&nbsp;Zheng previously served as chief strategy officer and director with AnHeart. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Interests include (i) 129,307 shares of common stock, (ii) 398,100 shares of common stock issuable upon
conversion of the Merger Conversion Shares, and (iii) 13,534 shares of common stock issuable upon exercise of the Merger Warrants. The principal business address for the entity named in this footnote is Room 2092, Floor 63, 11 Anning Zhuang Road,
Haidian District, Beijing City, China. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Interests include (a) (i) 994,671 shares of common stock, (ii) 3,062,500 shares of common stock issuable upon
conversion of the Merger Conversion Shares, and (iii) 104,112 shares of common stock issuable upon exercise of the Merger Warrants held by Octagon Investments Master Fund LP; (b) (i) 994,671 shares of common stock, (ii) 3,062,500 shares of common
stock issuable upon conversion of the Merger Conversion Shares, and (iii) 104,112 shares of common stock issuable upon exercise of the Merger Warrants held by Octagon Private Opportunities Fund LP; and (c) (i) 994,671 shares of common stock, (ii)
3,062,500 shares of common stock issuable upon conversion of the Merger Conversion Shares, and (iii) 104,112 shares of common stock issuable upon exercise of the Merger Warrants held by Octagon Special Opportunities Fund LP. The principal business
address for each entity named in this footnote is 654 Madison Avenue, 21<SUP STYLE="font-size:75%; vertical-align:top">st</SUP> Floor, New York, NY 10065. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Interests include (i) 39,786 shares of common stock, (ii) 122,400 shares of common stock issuable upon
conversion of the Merger Conversion Shares, and (iii) 4,164 shares of common stock issuable upon exercise of the Merger Warrants. The principal business address for the entity named in this footnote is 618 Waima Road, Huangpu District, Shanghai
City, China. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Interests include (i) 54,890 shares of common stock, (ii) 169,000 shares of common stock issuable upon
conversion of the Merger Conversion Shares, and (iii) 5,745 shares of common stock issuable upon exercise of the Merger Warrants. The principal business address for the entity named in this footnote is Floor 20, Xietai Center, 88 Zunyi South Road,
Changning District, Shanghai City, China. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Interests include (i) 1,591,475 shares of common stock, (ii) 4,900,000 shares of common stock issuable upon
conversion of the Merger Conversion Shares, and (iii) 166,579 shares of common stock issuable upon exercise of the Merger Warrants. The principal business address for the entity named in this footnote is Room 1801, 18<SUP
STYLE="font-size:75%; vertical-align:top">th</SUP> Floor, 1 Duddell Street, Central, Hong Kong. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(16)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Interests include (i) 497,336 shares of common stock, (ii) 1,531,200 shares of common stock issuable upon
conversion of the Merger Conversion Shares, and (iii) 52,056 shares of common stock issuable upon exercise of the Merger Warrants. The principal business address for the entity named in this footnote is Room 511, Building 1, 1318 Miaoxiang Road,
Lingang New Area, China (Shanghai) Free Trade Zone, Pudong New District, Shanghai City, China. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(17)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Interests include (i) 1,337,324 shares of common stock, (ii) 4,117,500 shares of common stock issuable upon
conversion of the Merger Conversion Shares, and (iii) 139,977 shares of common stock issuable upon exercise of the Merger Warrants. The principal business address for the entity named in this footnote is 250 North Bridge Road, <FONT
STYLE="white-space:nowrap">#11-01</FONT> Raffles City Tower, Singapore 179101. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(18)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Interests include (i) 3,477,805 shares of common stock, (ii) 10,707,900 shares of common stock issuable upon
conversion of the Merger Conversion Shares, and (iii) 364,021 shares of common stock issuable upon exercise of the Merger Warrants. The principal business address for the entity named in this footnote is Floor
<FONT STYLE="white-space:nowrap">21-23,</FONT> Building B, Donghai International Center, 7888 Shennan Avenue, Futian District, Shenzhen City, Guangdong Province, Chinas. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc881368_8"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are registering the issuance by us of up to 2,893,731shares of common stock that are issuable upon the exercise of the Merger Warrants by
the holders thereof. We are also registering the resale by the selling securityholders or their permitted transferees from time to time of (i)&nbsp;up to 115,660,186 shares of common stock (consisting of (a)&nbsp;up to 27,646,255 Merger Common
Shares, (b)&nbsp;up to 85,120,200 Merger Conversion Shares, and (c)&nbsp;up to 2,893,731 shares of common stock that are issuable upon the exercise of the Merger Warrants), and (ii)&nbsp;up to 2,893,731 Merger Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are required to pay all fees and expenses incident to the registration of the securities to be offered and sold pursuant to this
prospectus. The selling securityholders will bear all commissions and discounts, if any, attributable to their sale of securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
will not receive any of the proceeds from the sale of the securities by the selling securityholders. We will receive proceeds from Merger Warrants exercised in the event that such Merger Warrants are exercised for cash. The aggregate proceeds to the
selling securityholders will be the purchase price of the securities less any discounts and commissions borne by the selling securityholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of common stock and Merger Warrants beneficially owned by the selling securityholders covered by this prospectus may be offered and
sold from time to time by the selling securityholders, pursuant to the terms of the Certificate of Designation as applicable. The term &#147;selling securityholders&#148; includes donees, pledgees, transferees or other successors in interest selling
securities received after the date of this prospectus from a selling securityholder as a gift, pledge, partnership distribution or other transfer. The selling securityholders will act independently of us in making decisions with respect to the
timing, manner and size of each sale. Such sales may be made on one or more exchanges or in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise, at prices and under terms then
prevailing or at prices related to the then current market price or in negotiated transactions. The selling securityholders may sell their securities by one or more of, or a combination of, the following methods: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchases by a broker-dealer as principal and resale by such broker-dealer for its own account;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokerage transactions and transactions in which the broker solicits purchasers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">block trades in which the broker-dealer so engaged will attempt to sell the shares as agent but may position and
resell a portion of the block as principal to facilitate the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> or other
exchange distribution in accordance with the rules of the NYSE; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through trading plans entered into by a selling securityholder pursuant to Rule
<FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act, that are in place at the time of an offering pursuant to this prospectus and any applicable prospectus supplement hereto that provide for periodic sales of their securities on
the basis of parameters described in such trading plans; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">short sales; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">distribution to employees, members, limited partners or stockholders of the selling securityholders; through the
writing or settlement of options or other hedging transaction, whether through an options exchange or otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pledges to secure debts and other obligations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delayed delivery arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to or through underwriters or broker-dealers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;at the market&#148; offerings, as defined in Rule 415 under the Securities Act, at negotiated prices, at
prices prevailing at the time of sale or at prices related to such prevailing market prices, including sales made directly on a national securities exchange or sales made through a market maker other than on an exchange or other similar offerings
through sales agents; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">privately negotiated transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">options transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through a combination of any of the above methods of sale; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other method permitted pursuant to applicable law. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, any securities that qualify for sale pursuant to Rule 144 may be sold under Rule 144 rather than pursuant to this prospectus.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, a selling securityholder that is an entity may elect to make a pro rata <FONT STYLE="white-space:nowrap">in-kind</FONT>
distribution of securities to its members, partners or stockholders pursuant to the registration statement of which this prospectus is a part by delivering a prospectus with a plan of distribution. Such members, partners or stockholders would
thereby receive freely tradeable securities pursuant to the distribution through a registration statement. To the extent a distributee is an affiliate of ours (or to the extent otherwise required by law), we may, at our option, file a prospectus
supplement in order to permit the distributees to use the prospectus to resell the securities acquired in the distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent
required, this prospectus may be amended or supplemented from time to time to describe a specific plan of distribution. In connection with distributions of the securities or otherwise, the selling securityholders may enter into hedging transactions
with broker-dealers or other financial institutions. In connection with such transactions, broker-dealers or other financial institutions may engage in short sales of the securities in the course of hedging the positions they assume with selling
securityholders. The selling securityholders may also sell the securities short and redeliver the securities to close out such short positions. The selling securityholders may also enter into option or other transactions with broker-dealers or other
financial institutions which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this
prospectus (as supplemented or amended to reflect such transaction). The selling securityholders may also pledge securities to a broker-dealer or other financial institution, and, upon a default, such broker-dealer or other financial institution,
may effect sales of the pledged securities pursuant to this prospectus (as supplemented or amended to reflect such transaction). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
effecting sales, broker-dealers or agents engaged by the selling securityholders may arrange for other broker-dealers to participate. Broker-dealers or agents may receive commissions, discounts or concessions from the selling securityholders in
amounts to be negotiated immediately prior to the sale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In offering the securities covered by this prospectus, and any broker-dealers who
execute sales for selling securityholders may be deemed to be &#147;underwriters&#148; within the meaning of the Securities Act in connection with such sales. Any compensation of any broker-dealer who executes sales for them, may be deemed to be
underwriting discounts and commissions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have advised the selling securityholders that the anti-manipulation rules of Regulation M
under the Exchange Act may apply to sales of securities in the market and to the activities of the selling securityholders and their affiliates. In addition, we will make copies of this prospectus available to the selling securityholders for the
purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling securityholders may indemnify any broker-dealer that participates in transactions involving the sale of the securities against certain liabilities,
including liabilities arising under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the time a particular offer of securities is made, if required, a prospectus
supplement will be distributed that will set forth the number of securities being offered and the terms of the offering, including the name of any underwriter, dealer or agent, the purchase price paid by any underwriter, any discount, commission and
other item constituting compensation, any discount, commission or concession allowed or reallowed or paid to any dealer, and the proposed selling price to the public. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder of Merger Warrants may exercise its Merger Warrants in accordance with the Amended
and Restated Warrant Agreement, dated April&nbsp;9, 2024 (the &#147;warrant agreement&#148;), on or before the expiration date set forth therein by surrendering, at the office of the warrant agent, Continental Stock Transfer&nbsp;&amp; Trust
Company, the certificate evidencing such Merger Warrant, with the form of election to purchase set forth thereon, properly completed and duly executed, accompanied by full payment of the exercise price and any and all applicable taxes due in
connection with the exercise of the Merger Warrant, subject to any applicable provisions relating to cashless exercises in accordance with the warrant agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify certain of the selling securityholders against certain liabilities, including liabilities under the Securities Act
and state securities laws, relating to the registration of the warrants or shares offered by this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed with the
selling securityholders to keep the registration statement of which this prospectus constitutes a part effective until such time as all of the securities covered by this prospectus have been disposed of pursuant to and in accordance with the
registration statement or such securities have been withdrawn. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc881368_9"></A>DESCRIPTION OF SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following is a summary of the rights of our common stock and preferred stock. This summary is qualified by reference to the complete text of our
amended and restated certificate of incorporation and amended and restated bylaws filed as exhibits to the registration statement of which this prospectus forms a part. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of
incorporation authorizes us to issue up to 1,000,000,000 shares of our Class&nbsp;A common stock, par value $0.0001 per share (&#147;Class&nbsp;A common stock&#148;), 60,000,000 shares of our Class&nbsp;B common stock, par value $0.0001 per share
(&#147;Class&nbsp;B common stock&#148; and together with the Class&nbsp;A common stock, the &#147;Common Stock&#148;), and 10,000,000 shares of our preferred stock, par value $0.0001 per share, of which 851,212 shares have been designated as Series
A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Convertible Preferred Stock (&#147;Series A Preferred Stock&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each holder of Class&nbsp;A common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election
of directors, except for the directors who are elected exclusively by the holders of Class&nbsp;B common stock. The holders of Class&nbsp;A common stock do not have cumulative voting rights in the election of directors. Holders of Class&nbsp;B
common stock are entitled to one vote for each share held of record on all matters submitted to a vote of stockholders, including the election or removal of directors. The holders of Class&nbsp;B common stock do not have cumulative voting rights in
the election of directors. Holders of Common Stock vote together as a single class on all matters, except that (i)&nbsp;the holders of Class&nbsp;B common stock have the right, voting as a separate class, to elect and remove without cause three
directors plus at least 50% of any directors in excess of seven, and (ii)&nbsp;the approval of the holders of a majority of Class&nbsp;B common stock, voting as a separate class, is required for approval by the stockholders of any acquisition
(whether by merger, sale of shares or sale of assets) or liquidation. Each share of Class&nbsp;B common stock will automatically convert into one share of Class&nbsp;A common stock upon transfer to a
<FONT STYLE="white-space:nowrap">non-authorized</FONT> holder. In addition, the Class&nbsp;B common stock is subject to a &#147;sunset&#148; provision under which all outstanding shares of Class&nbsp;B common stock will automatically convert into an
equal number of shares of Class&nbsp;A common stock if ownership of shares of Class&nbsp;A and Class&nbsp;B common stock held by our President and Chief executive Officer, Dr.&nbsp;David Hung, falls below an aggregate of 43,188,000 shares or if
Dr.&nbsp;Hung dies, becomes disabled or ceases to be our Chief Executive Officer, unless he is terminated from such position by us without cause. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon
our liquidation, dissolution or winding up and after payment in full of all amounts required to be paid to creditors and to the holders of preferred stock having liquidation preferences, if any, the holders of any shares of Common Stock (and the
holders of any preferred stock that may then be outstanding, to the extent required by our charter, including any certificate of designation with respect to any series of preferred stock) will be entitled to receive pro rata of our remaining assets
available for distribution, unless holders of a majority of the outstanding shares of Class&nbsp;A common stock and Class&nbsp;B common stock voting together approve a different treatment of the shares. Holders of Common Stock do not have
preemptive, subscription, redemption or conversion rights. The Common Stock will not be subject to further calls or assessment by us. There will be no redemption or sinking fund provisions applicable to any shares of Common Stock. All shares of
Common Stock that will be outstanding at the effective time will be fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> The rights, powers, preferences and privileges of holders of Common Stock will be subject to those of the
holders of any shares of preferred stock New we may authorize and issue in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under our amended and restated certificate of incorporation our board of directors may, without further action by our stockholders, fix the rights,
preferences, privileges and restrictions of up to an aggregate of 10,000,000 shares of preferred stock in one or more series and authorize their issuance. These rights, preferences and privileges </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences and the number of shares constituting any series or the designation of such series,
any or all of which may be greater than the rights of Class&nbsp;A common stock. There is no restriction on the repurchase or redemption of shares of preferred stock by the Company while there is any arrearage in the payment of dividends or sinking
fund installments. Any issuance of preferred stock could adversely affect the voting power of holders of Common Stock and the likelihood that such holders would receive dividend payments and payments on liquidation. In addition, the issuance of
preferred stock could have the effect of delaying, deterring or preventing a change of control or other corporate action. We have no current plan to issue any shares of preferred stock other than the shares of our Series A Preferred Stock that were
issued in connection with the Acquisition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series A Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of Series A Preferred Stock are entitled to receive dividends on shares of Series A Preferred Stock equal to, on <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">an&nbsp;as-if-converted-to-common-stock&nbsp;basis,</FONT></FONT></FONT></FONT> and in the same form as dividends actually paid on shares of our Common
Stock. Except as provided in the Certificate of Designation or as otherwise required by law, the Series&nbsp;A Preferred Stock does not have voting rights. However, as long as any shares of Series A Preferred Stock are outstanding, we will not,
without the affirmative vote of the holders of a majority of the then outstanding shares of the Series A Preferred Stock: (a)&nbsp;alter or change adversely the powers, preferences or rights given to the Series&nbsp;A Preferred Stock, or alter or
amend the Certificate of Designation, amend or repeal any provision of, or add any provision to, the Company&#146;s Certificate of Incorporation or its Bylaws, or file any articles of amendment, certificate of designations, preferences, limitations
and relative rights of any series of Preferred Stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series A Preferred Stock, regardless of whether
any of the foregoing actions will be by means of amendment to the Certificate of Incorporation or by merger, consolidation, recapitalization, reclassification, conversion or otherwise, (b)&nbsp;issue further shares of Series A Preferred Stock or
increase or decrease (other than by conversion) the number of authorized shares of Series A Preferred Stock, (c)&nbsp;prior to Stockholder Approval (as defined in the Certificate of Designation) or at any time while at least 30% of the originally
issued Series A Preferred Stock remains issued and outstanding, consummate (x)&nbsp;any Fundamental Transaction (as defined in the Certificate of Designation) or (y)&nbsp;any merger or consolidation of the Company with or into another entity or any
stock sale to, or other business combination in which the stockholders of the Company immediately before such transaction do not hold at least a majority of the capital stock of the Company immediately after such transaction or (d)&nbsp;enter into
any agreement with respect to any of the foregoing. The Series A Preferred Stock does not have a preference upon any liquidation, dissolution <FONT STYLE="white-space:nowrap">or&nbsp;winding-up&nbsp;of</FONT> the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following Stockholder Approval, each share of Series A Preferred Stock will automatically convert into 100 shares of Class&nbsp;A common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Public Stockholders&#146; Warrants
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of July&nbsp;31, 2024, there were 8,681,182 warrants to purchase common stock outstanding. Each whole warrant entitles the registered holder to
purchase one share of our Class&nbsp;A common stock at a price of $11.50 per share, subject to adjustment as discussed below. Pursuant to the warrant agreement, a warrant holder may exercise its warrants only for a whole number of shares of our
Class&nbsp;A common stock. This means only a whole warrant may be exercised at a given time by a warrant holder. The warrants will expire on the fifth anniversary of the completion of the Business Combination (as defined in the warrant agreement),
at 5:00 p.m., New York City time, or earlier upon redemption; <I>provided, however</I>, that Private Placement Warrants (as defined in the warrant agreement) issued to PA <FONT STYLE="white-space:nowrap">Co-Investment</FONT> LLC will not be
exercisable more than five years from the effective date of the registration statement with respect to the Panacea initial public offering in accordance with FINRA Rule&nbsp;5110(f)(2)(G)(i). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will not be obligated to deliver any shares of Class&nbsp;A common stock pursuant to the exercise of a warrant and will have no obligation to settle such
warrant exercise unless a registration statement under the Securities Act </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
covering the issuance of the shares of Class&nbsp;A common stock issuable upon exercise of the warrants is then effective and a current prospectus relating to those shares of Class&nbsp;A common
stock is available, subject to our satisfying our obligations described below with respect to registration. No warrant will be exercisable for cash or on a cashless basis, and we will not be obligated to issue any shares to holders seeking to
exercise their warrants, unless the issuance of the shares upon such exercise is registered or qualified under the securities laws of the state of the exercising holder, or an exemption from registration is available. In the event that the
conditions in the two immediately preceding sentences are not satisfied with respect to a warrant, the holder of such warrant will not be entitled to exercise such warrant and such warrant may have no value and expire worthless. In no event will we
be required to net cash settle any warrant. We have agreed to maintain a current prospectus relating to shares of Class&nbsp;A common stock issuable upon exercise of the warrants until the warrants expire or are redeemed. Notwithstanding the above,
if our Class&nbsp;A common stock is at the time of any exercise of a warrant not listed on a national securities exchange such that it satisfies the definition of a &#147;covered security&#148; under Section&nbsp;18(b)(1) of the Securities Act, we
may, at our option, require holders of warrants who exercise their warrants to do so on a &#147;cashless basis&#148; in accordance with Section&nbsp;3(a)(9) of the Securities Act and, in the event we so elect, we will not be required to file or
maintain in effect a registration statement, but will use our commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. In such event, each holder would pay the
exercise price by surrendering the warrants for that number of shares of Class&nbsp;A common stock equal to the lesser of (A)&nbsp;the quotient obtained by dividing (x)&nbsp;the product of the number of shares of Class&nbsp;A common stock underlying
the warrants, multiplied by the excess of the &#147;fair market value&#148; (defined below) less the exercise price of the warrants by (y)&nbsp;the fair market value and (B) 0.361. The &#147;fair market value&#148; for this purpose shall mean the
volume weighted average price of the Class&nbsp;A common stock for the 10 trading days ending on the trading day prior to the date on which the notice of exercise is received by the warrant agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redemption of warrants when the price per share of Class</I></B><B><I></I></B><B><I>&nbsp;A common stock equals or exceeds $18.00.</I></B>&nbsp;Once the
warrants become exercisable, we may redeem the outstanding warrants (except as described herein with respect to the Private Placement Warrants): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in whole and not in part; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a price of $0.01 per warrant; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon a minimum of 30 days&#146; prior written notice of redemption, or the
<FONT STYLE="white-space:nowrap">30-day</FONT> redemption period, to each warrant holder; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if, and only if, the last reported sale price of our Class&nbsp;A common stock equals or exceeds $18.00 per share
(as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a <FONT STYLE="white-space:nowrap">30-trading</FONT> day period ending on the third trading day prior to the date on
which we send the notice of redemption to the warrant holders. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If and when the warrants become redeemable by us, we may exercise our
redemption right even if we are unable to register or qualify the underlying securities for sale under all applicable state securities laws. As a result, we may redeem warrants even if the holders are otherwise unable to exercise their warrants.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have established the $18.00 per share (as adjusted) redemption criteria discussed above to prevent a redemption call unless there is at the time of
the call a significant premium to the warrant exercise price. If the foregoing conditions are satisfied and we issue a notice of redemption of the warrants, each warrant holder will be entitled to exercise its warrant prior to the scheduled
redemption date. However, the price of the Class&nbsp;A common stock may fall below the $18.00 redemption trigger price (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) as well as the $11.50 warrant
exercise price after the redemption notice is issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redemption of warrants when the price per share of Class</I></B><B><I></I></B><B><I>&nbsp;A
common stock equals or exceeds $10.00.</I></B>&nbsp;Commencing 90 days after the warrants become exercisable, we may redeem the outstanding warrants (except as described herein with respect to the Private Placement Warrants): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in whole and not in part; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a price of $0.10 per warrant provided that holders will be able to exercise their warrants prior to redemption
and receive that number of shares of Class&nbsp;A common stock determined by reference to the table below, based on the redemption date and the &#147;fair market value&#148; of our Class&nbsp;A common stock (as defined below) except as otherwise
described below; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon a minimum of 30 days&#146; prior written notice of redemption; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if, and only if, the last reported sale price of our Class&nbsp;A common stock equals or exceeds $10.00 per share
(as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) on the trading day prior to the date on which we send the notice of redemption to the warrant holders; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if, and only if, there is an effective registration statement covering the issuance of the shares of Class&nbsp;A
common stock issuable upon exercise of the warrants and a current prospectus relating thereto available throughout the <FONT STYLE="white-space:nowrap">30-day</FONT> period after written notice of redemption is given. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The numbers in the table below represent the number of shares of Class&nbsp;A common stock that a warrant holder will receive upon cashless exercise in
connection with a redemption by us pursuant to this redemption feature, based on the &#147;fair market value&#148; of our Class&nbsp;A common stock on the corresponding redemption date (assuming holders elect to exercise their warrants and such
warrants are not redeemed for $0.10 per warrant), determined based on the average of the last reported sales price for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of
warrants, and the number of months that the corresponding redemption date precedes the expiration date of the warrants, each as set forth in the table below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The stock prices set forth in the column headings of the table below will be adjusted as of any date on which the number of shares issuable upon exercise of a
warrant is adjusted as set forth in the first three paragraphs under the heading &#147;&#151; Anti-dilution Adjustments&#148; below. The adjusted stock prices in the column headings will equal the stock prices immediately prior to such adjustment,
multiplied by a fraction, the numerator of which is the number of shares deliverable upon exercise of a warrant immediately prior to such adjustment and the denominator of which is the number of shares deliverable upon exercise of a warrant as so
adjusted. The number of shares in the table below shall be adjusted in the same manner and at the same time as the number of shares issuable upon exercise of a warrant. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2"><B>Redemption Date (period to expiration of <BR>warrants)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="34" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Market Value of Class&nbsp;A Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B></B>&#8804;<B></B><B>$10.00</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$11.00</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$12.00</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$13.00</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$14.00</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$15.00</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$16.00</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$17.00</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B></B>&#8805;<B></B><B>$18.00</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">57 months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">54 months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">51 months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">48 months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">45 months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">42 months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">39 months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">36 months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">33 months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">30 months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">27 months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">24 months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21 months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18 months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15 months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12 months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9 months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6 months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3 months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">0 months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exact fair market value and redemption date may not be set forth in the table above, in which case, if
the fair market value is between two values in the table or the redemption date is between two redemption dates in the table, the number of shares of Class&nbsp;A common stock to be issued for each warrant exercised will be determined by a
straight-line interpolation between the number of shares set forth for the higher and lower fair market values and the earlier and later redemption dates, as applicable, based on a 365 or <FONT STYLE="white-space:nowrap">366-day</FONT> year, as
applicable. For example, if the average last reported sale price of our Class&nbsp;A common stock for the 10 trading days ending on the third trading date prior to the date on which the notice of redemption is sent to the holders of the warrants is
$11 per share, and at such time there are 57 months until the expiration of the warrants, holders may choose to, in connection with this redemption feature, exercise their warrants for 0.277 shares of Class&nbsp;A common stock for each whole
warrant. For an example where the exact fair market value and redemption date are not as set forth in the table above, if the average last reported sale price of our Class&nbsp;A common stock for the 10 trading days ending on the third trading date
prior to the date on which the notice of redemption is sent to the holders of the warrants is $13.50 per share, and at such time there are 38 months until the expiration of the warrants, holders may choose to, in connection with this redemption
feature, exercise their warrants for 0.298 shares of Class&nbsp;A common stock for each whole warrant. In no event will the warrants be exercisable in connection with this redemption feature for more than 0.361 shares of Class&nbsp;A common stock
per warrant (subject to adjustment). Finally, as reflected in the table above, if the warrants are out of the money and about to expire, they cannot be exercised on a cashless basis in connection with a redemption by us pursuant to this redemption
feature, since they will not be exercisable for any shares of Class&nbsp;A common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any Publicly Traded Warrants (as defined in the warrant
agreement) held by our officers or directors will be subject to this redemption feature, except that such officers and directors shall only receive &#147;fair market value&#148; for such Publicly Traded Warrants if they exercise their Publicly
Traded Warrants in connection with such redemption (&#147;fair market value&#148; for such Publicly Traded Warrants held by our officers or directors being defined as the last reported sale price of the Publicly Traded Warrants on such redemption
date). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This redemption feature differs from the typical warrant redemption features used in many other blank check offerings, which typically only
provide for a redemption of warrants for cash (other than the Private Placement Warrants) when the trading price for the Class&nbsp;A common stock exceeds $18.00 per share for a specified period of time. This redemption feature is structured to
allow for all of the outstanding warrants (other than the Private Placement Warrants) to be redeemed when the Class&nbsp;A common stock is trading at or above $10.00 per share, which may be at a time when the trading price of our Class&nbsp;A common
stock is below the exercise price of the warrants. We have established this redemption feature to provide us with the flexibility to redeem the warrants without the warrants having to reach the $18.00 per share threshold set forth above under
&#147;&#151; <I>Redemption of warrants when the price per share of Class</I><I></I><I>&nbsp;A common stock equals or exceeds $18.00</I>.&#148; Holders choosing to exercise their warrants in connection with a redemption pursuant to this feature will,
in effect, receive a number of shares for their warrants based on an option pricing model with a fixed volatility input as of the date of the Panacea initial public offering. This redemption right provides us an additional mechanism by which to
redeem all of the outstanding warrants, and therefore have certainty as to our capital structure as the warrants would no longer be outstanding and would have been exercised or redeemed, and we will effectively be required to pay the redemption
price to warrant holders if we choose to exercise this redemption right and it will allow us to quickly proceed with a redemption of the warrants if we determine it is in our best interest to do so. As such, we would redeem the warrants in this
manner when we believe it is in our best interest to update our capital structure to remove the warrants and pay the redemption price to the warrant holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As stated above, we can redeem the warrants when the Class&nbsp;A common stock is trading at a price starting at $10.00, which is below the exercise price of
$11.50, because it will provide certainty with respect to our capital structure and cash position while providing warrant holders with the opportunity to exercise their warrants on a cashless basis for the applicable number of shares of Class&nbsp;A
common stock. If we choose to redeem the warrants when the Class&nbsp;A common stock is trading at a price below the exercise price of the warrants, this could result in the warrant holders receiving fewer shares of Class&nbsp;A common stock than
they would have received if they had </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
chosen to wait to exercise their warrants for shares of Class&nbsp;A common stock if and when shares of Class&nbsp;A common stock were trading at a price higher than the exercise price of $11.50
per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No fractional shares of Class&nbsp;A common stock will be issued upon exercise. If, upon exercise, a holder would be entitled to receive a
fractional interest in a share, we will round down to the nearest whole number of the number of shares of Class&nbsp;A common stock to be issued to the holder. If, at the time of redemption, the warrants are exercisable for a security other than the
shares of Class&nbsp;A common stock pursuant to the warrant agreement, the warrants may be exercised for such security. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redemption Procedures and
Cashless Exercise.</I></B>&nbsp;If we call the warrants for redemption as described above under <I>&#147;&#151; Redemption of warrants when the price per share of Class</I><I></I><I>&nbsp;A common stock equals or exceeds $18.00</I>,&#148; our
management will have the option to require all holders that wish to exercise warrants to do so on a &#147;cashless basis&#148; (such option, the &#147;Cashless Exercise Option&#148;). In determining whether to require all holders to exercise their
warrants on a &#147;cashless basis,&#148; our management will consider, among other factors, our cash position, the number of warrants that are outstanding and the dilutive effect on our stockholders of issuing the maximum number of shares of
Class&nbsp;A common stock issuable upon the exercise of our warrants. In such event, each holder would pay the exercise price by surrendering the warrants for that number of shares of Class&nbsp;A common stock equal to the lesser of (A)&nbsp;the
quotient obtained by dividing (x)&nbsp;the product of the number of shares of Class&nbsp;A common stock underlying the warrants, multiplied by the excess of the &#147;fair market value&#148; (defined below) over the exercise price of the warrants by
(y)&nbsp;the fair market value and (B) 0.361. The &#147;fair market value&#148; for this purpose shall mean the average last reported sale price of the Class&nbsp;A common stock for the 10 trading days ending on the third trading day prior to the
date on which the notice of redemption is sent to the holders of warrants. If our management takes advantage of this Cashless Exercise Option, the notice of redemption will contain the information necessary to calculate the number of shares of
Class&nbsp;A common stock to be received upon exercise of the warrants, including the &#147;fair market value&#148; in such case. Requiring a cashless exercise in this manner will reduce the number of shares to be issued and thereby lessen the
dilutive effect of a warrant redemption. We believe this Cashless Exercise Option feature is an attractive option to us if we do not need the cash from the exercise of the warrants after our initial business combination. If we call our warrants for
redemption and our management does not take advantage of this Cashless Exercise Option, the Founders and their permitted transferees would still be entitled to exercise their Private Placement Warrants for cash or on a cashless basis using the same
formula described above that other warrant holders would have been required to use had management taken advantage of this Cashless Exercise Option, as described in more detail below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A holder of a warrant may notify us in writing in the event it elects to be subject to a requirement that such holder will not have the right to exercise such
warrant, to the extent that after giving effect to such exercise, such person (together with such person&#146;s affiliates), would beneficially own in excess of 9.8% (or such other amount as a holder may specify) of the shares of Class&nbsp;A common
stock outstanding immediately after giving effect to such exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anti-Dilution Adjustments.</I></B>&nbsp;If the number of outstanding shares of
Class&nbsp;A common stock is increased by a stock dividend payable in shares of Class&nbsp;A common stock, or by a <FONT STYLE="white-space:nowrap">split-up</FONT> of shares of Class&nbsp;A common stock or other similar event, then, on the effective
date of such stock dividend, <FONT STYLE="white-space:nowrap">split-up</FONT> or similar event, the number of shares of Class&nbsp;A common stock issuable on exercise of each warrant will be increased in proportion to such increase in the
outstanding shares of Class&nbsp;A common stock. A rights offering to holders of Class&nbsp;A common stock entitling holders to purchase shares of Class&nbsp;A common stock at a price less than the fair market value will be deemed a stock dividend
of a number of shares of Class&nbsp;A common stock equal to the product of (1)&nbsp;the number of shares of Class&nbsp;A common stock actually sold in such rights offering (or issuable under any other equity securities sold in such rights offering
that are convertible into or exercisable for Class&nbsp;A common stock) multiplied by (2)&nbsp;one minus the quotient of (x)&nbsp;the price per share of Class&nbsp;A common stock paid in such rights offering divided by (y)&nbsp;the fair market
value. For these purposes (1)&nbsp;if the rights offering is for securities convertible into or exercisable for Class&nbsp;A common stock, in determining the price payable for Class&nbsp;A common stock, there will be taken into account any
consideration received for such rights, as well as any additional </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amount payable upon exercise or conversion and (2)&nbsp;fair market value means the volume weighted average price of Class&nbsp;A common stock as reported during the ten trading day period ending
on the trading day prior to the first date on which the shares of Class&nbsp;A common stock trade on the applicable exchange or in the applicable market, regular way, without the right to receive such rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, if we, at any time while the warrants are outstanding and unexpired, pay a dividend or make a distribution in cash, securities or other assets to
the holders of Class&nbsp;A common stock on account of such shares of Class&nbsp;A common stock (or other shares of our capital stock into which the warrants are convertible), other than as described above or certain ordinary cash dividends, then
the warrant exercise price will be decreased, effective immediately after the effective date of such event, by the amount of cash and/or the fair market value of any securities or other assets paid on each share of Class&nbsp;A common stock in
respect of such event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the number of outstanding shares of our Class&nbsp;A common stock is decreased by a consolidation, combination, reverse stock
split or reclassification of shares of Class&nbsp;A common stock or other similar event, then, on the effective date of such consolidation, combination, reverse stock split, reclassification or similar event, the number of shares of Class&nbsp;A
common stock issuable on exercise of each warrant will be decreased in proportion to such decrease in outstanding shares of Class&nbsp;A common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whenever the number of shares of Class&nbsp;A common stock purchasable upon the exercise of the warrants is adjusted, as described above, the warrant exercise
price will be adjusted by multiplying the warrant exercise price immediately prior to such adjustment by a fraction (x)&nbsp;the numerator of which will be the number of shares of Class&nbsp;A common stock purchasable upon the exercise of the
warrants immediately prior to such adjustment, and (y)&nbsp;the denominator of which will be the number of shares of Class&nbsp;A common stock so purchasable immediately thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In case of any reclassification or reorganization of the outstanding shares of Class&nbsp;A common stock (other than those described above or that solely
affects the par value of such shares of Class&nbsp;A common stock), or in the case of any merger or consolidation of us with or into another corporation (other than a merger or consolidation in which we are the continuing corporation and that does
not result in any reclassification or reorganization of our outstanding shares of Class&nbsp;A common stock), or in the case of any sale or conveyance to another corporation or entity of the assets or other property of us as an entirety or
substantially as an entirety in connection with which we are dissolved, the holders of the warrants will thereafter have the right to purchase and receive, upon the basis and upon the terms and conditions specified in the warrants and in lieu of the
shares of our Class&nbsp;A common stock immediately theretofore purchasable and receivable upon the exercise of the rights represented thereby, the kind and amount of shares of stock or other securities or property (including cash) receivable upon
such reclassification, reorganization, merger or consolidation, or upon a dissolution following any such sale or transfer, that the holder of the warrants would have received if such holder had exercised their warrants immediately prior to such
event. However, if such holders were entitled to exercise a right of election as to the kind or amount of securities, cash or other assets receivable upon such merger or consolidation, then the kind and amount of securities, cash or other assets for
which each warrant will become exercisable will be deemed to be the weighted average of the kind and amount received per share by such holders in such merger or consolidation that affirmatively make such election, and if a tender, exchange or
redemption offer has been made to and accepted by such holders under circumstances in which, upon completion of such tender or exchange offer, the maker thereof, together with members of any group (within the meaning of Rule <FONT
STYLE="white-space:nowrap">13d-5(b)(1)</FONT> under the Exchange Act) of which such maker is a part, and together with any affiliate or associate of such maker (within the meaning of Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the
Exchange Act) and any members of any such group of which any such affiliate or associate is a part, own beneficially (within the meaning of Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act) more than 50% of the outstanding
shares of Class&nbsp;A common stock, the holder of a warrant will be entitled to receive the highest amount of cash, securities or other property to which such holder would actually have been entitled as a stockholder if such warrant holder had
exercised the warrant prior to the expiration of such tender or exchange offer, accepted such offer and all of the Class&nbsp;A common stock held by such holder had been purchased pursuant to such tender or exchange offer, subject to adjustments
(from and after the consummation of such tender or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exchange offer) as nearly equivalent as possible to the adjustments provided for in the warrant agreement. Additionally, if less than 70% of the consideration receivable by the holders of
Class&nbsp;A common stock in such a transaction is payable in the form of Class&nbsp;A common stock in the successor entity that is listed for trading on a national securities exchange or is quoted in an established <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market, or is to be so listed for trading or quoted immediately following such event, and if the registered holder of the warrant properly exercises the warrant within thirty days following
public disclosure of such transaction, the warrant exercise price will be reduced as specified in the warrant agreement based on the per share consideration minus Black-Scholes Warrant Value (as defined in the warrant agreement) of the warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The warrants have been issued in registered form under a warrant agreement between Continental Stock Transfer&nbsp;&amp; Trust Company, as warrant agent, and
us. Warrant holders should review a copy of the warrant agreement, which is filed as an exhibit to the Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> with respect to the closing of the Acquisition, for a description of the terms
and conditions applicable to the warrants. The warrant agreement provides that (a)&nbsp;the terms of the warrants may be amended without the consent of any holder for the purpose of (i)&nbsp;curing any ambiguity or correct any mistake, including to
conform the provisions of the warrant agreement to the description of the terms of the warrants and the warrant agreement set forth in this prospectus, or defective provision or (ii)&nbsp;adding or changing any provisions with respect to matters or
questions arising under the warrant agreement as the parties to the warrant agreement may deem necessary or desirable and that the parties deem to not adversely affect the rights of the registered holders of the warrants and (b)&nbsp;all other
modifications or amendments require the vote or written consent of at least 50% of the then outstanding Publicly Traded Warrants and, solely with respect to any amendment to the terms of the Private Placement Warrants or Forward Purchase Warrants
(as defined in the warrant agreement) or any provision of the warrant agreement with respect to the Private Placement Warrants or Forward Purchase Warrants, at least 50% of the then outstanding Private Placement Warrants or Forward Purchase
Warrants, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The warrant holders do not have the rights or privileges of holders of Class&nbsp;A common stock and any voting rights until they
exercise their warrants and receive shares of Class&nbsp;A common stock. After the issuance of shares of Class&nbsp;A common stock upon exercise of the warrants, each holder will be entitled to one vote for each share of Class&nbsp;A common stock
held of record on all matters to be voted on by stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Provisions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;203 of the Delaware General Corporation Law </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to Section&nbsp;203 of the Delaware General Corporation Law, which generally prohibits a publicly held Delaware corporation from engaging in any
business combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">before such date, the board of directors of the corporation approved either the business combination or the
transaction that resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the
interested stockholder, those shares owned (1)&nbsp;by persons who are directors and also officers and (2)&nbsp;employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the
plan will be tendered in a tender or exchange offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on or after such date, the business combination is approved by the board of directors and authorized at an annual
or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 662/3% of the outstanding voting stock that is not owned by the interested stockholder. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines a &#147;business combination&#148; to include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any merger or consolidation involving the corporation and the interested stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the
interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any
stock of the corporation to the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock
or any class or series of the corporation beneficially owned by the interested stockholder; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other
financial benefits by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines an &#147;interested stockholder&#148; as an
entity or person who, together with the person&#146;s affiliates and associates, beneficially owns or within three years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the
corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Delaware corporation may &#147;opt out&#148; of these provisions with an express provision in its original certificate of incorporation or
an express provision in its amended and restated certificate of incorporation or amended and restated bylaws resulting from a stockholders&#146; amendment approved by at least a majority of the outstanding voting shares. We have not opted out of
these provisions. As a result, mergers or other takeover or change in control attempts of us may be discouraged or prevented. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certificate of
Incorporation and Bylaws </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Among other things, our amended and restated certificate of incorporation and amended and restated bylaws: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">permits our board of directors to issue up to 10,000,000 shares of preferred stock, with any rights, preferences
and privileges as they may designate, including the right to approve an acquisition or other change of control; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provides that the authorized number of directors may be changed only by resolution of our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provides that, subject to the rights of any series of preferred stock to elect directors, directors may only be
removed for cause, which removal may be effected, subject to any limitation imposed by law, by the holders of at least 662/3% of the voting power of all of our then-outstanding shares of the capital stock entitled to vote generally at an election of
directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provides that all vacancies, including newly created directorships, may, except as otherwise required by law, be
filled by the affirmative vote of a majority of directors then in office, even if less than a quorum; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requires that any action to be taken by our stockholders must be effected at a duly called annual or special
meeting of stockholders and not be taken by written consent or electronic transmission; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provides that stockholders seeking to present proposals before a meeting of stockholders or to nominate
candidates for election as directors at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder&#146;s notice; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provides that special meetings of our stockholders may be called only by the chairperson of our board of
directors, our chief executive officer or by our board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">does not provide for cumulative voting rights, therefore allowing the holders of a majority of the shares of
common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The combination of these provisions may make it more difficult for our existing stockholders to replace our board of directors as well as for another party to
obtain control of us by replacing our board of directors. Since our board of directors has the power to retain and discharge our officers, these provisions could also make it more difficult for existing stockholders or another party to effect a
change in management. In addition, the authorization of undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to
change our control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and its
policies and to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to reduce our vulnerability to hostile takeovers and to discourage certain tactics that may be used in proxy fights. However,
such provisions could have the effect of discouraging others from making tender offers for our shares and may have the effect of delaying changes in our control or management. As a consequence, these provisions may also inhibit fluctuations in the
market price of our stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the
exclusive forum for actions or proceedings brought under Delaware statutory or common law: (1)&nbsp;any derivative action or proceeding brought on our behalf; (2)&nbsp;any action asserting a breach of fiduciary duty; (3)&nbsp;any action asserting a
claim against us arising under the Delaware General Corporation Law; (4)&nbsp;any action regarding the certificate of incorporation or our amended and restated bylaws; (5)&nbsp;any action as to which the Delaware General Corporate Law confers
jurisdiction to the Court of Chancery of the State of Delaware; or (6)&nbsp;any action asserting a claim against us that is governed by the internal affairs doctrine. Our amended and restated certificate of incorporation further provides that the
federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act
or the rules and regulations thereunder. As a result, the exclusive forum provision of our amended and restated certificate of incorporation will not apply to suits brought to enforce any duty or liability created by the Exchange Act or any other
claim for which the federal courts have exclusive jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we believe this provision benefits us by providing increased consistency in the
application of Delaware law in the types of lawsuits to which it applies, a court may determine that this provision is unenforceable, and to the extent it is enforceable, the provision may have the effect of discouraging lawsuits against our
directors and officers, although our stockholders will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder and therefore bring a claim in another appropriate forum. Additionally, we
cannot be certain that a court will decide that this provision is either applicable or enforceable, and if a court were to find the choice of forum provision contained in the amended and restated certificate of incorporation to be inapplicable or
unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, operating results and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transfer agent for our securities is
Continental Stock Transfer&nbsp;&amp; Trust Company. The transfer agent&#146;s address is One State Street Plaza, 30th Floor New York, New York 10004. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc881368_10"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cooley LLP will pass upon the validity of the securities offered hereby. As of the date of this prospectus, GC&amp;H Investments, LLC, which
is an entity beneficially owned by current and former partners and employees of Cooley LLP, beneficially owns an aggregate of 25,410 shares of our common stock, and attorneys with Cooley LLP beneficially hold an aggregate of 22,500 additional shares
of our common stock. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc881368_11"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Nuvation Bio Inc. and its subsidiaries as of December&nbsp;31, 2023 and 2022, and for each of the
years in the <FONT STYLE="white-space:nowrap">two-year</FONT> period ended December&nbsp;31, 2023, have been incorporated by reference herein in reliance upon the report of KPMG LLP, independent registered public accounting firm, incorporated by
reference herein, and upon the authority of said firm as experts in accounting and auditing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements of AnHeart
Therapeutics Ltd. as of December&nbsp;31, 2023 and 2022, and for each of the two years in the period ended December&nbsp;31, 2023, incorporated by reference in this prospectus, have been audited by Deloitte Touche Tohmatsu Certified Public
Accountants LLP, an independent auditor, as stated in their report. Such financial statements are incorporated by reference in reliance upon the report of such firm given their authority as experts in accounting and auditing. The office of Deloitte
Touche Tohmatsu Certified Public Accountants LLP is located at Hangzhou, the People&#146;s Republic of China. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc881368_12"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> under the Securities Act, with
respect to the securities being offered by this prospectus. This prospectus, which constitutes part of the registration statement, does not contain all of the information in the registration statement and its exhibits. For further information with
respect to us and our securities offered by this prospectus, we refer you to the registration statement and its exhibits. Statements contained in this prospectus as to the contents of any contract or any other document referred to are not
necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed as an exhibit to the registration statement. Each of these statements is qualified in all respects by this reference. You can read our SEC
filings, including the registration statement, over the internet at the SEC&#146;s website at <I>www.sec.gov</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the
information reporting requirements of the Exchange Act, and we file reports, proxy statements and other information with the SEC. These reports, proxy statements and other information will be available for review at the SEC&#146;s website at
<I>www.sec.gov</I>. We also maintain a website at <I>www.nuvationbio.com. </I>Through our website, we make available, free of charge, the following documents as soon as reasonably practicable after they are electronically filed with, or furnished
to, the SEC: our Annual Reports on Form <FONT STYLE="white-space:nowrap">10-K;</FONT> our proxy statements for our annual and special stockholder meetings; our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q;</FONT> our Current
Reports on Form <FONT STYLE="white-space:nowrap">8-K;</FONT> Forms 3, 4 and 5 and Schedules 13D; and amendments to those documents. The information contained in, or that can be accessed through, our website is not part of, and is not incorporated
into, this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc881368_13"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; the information we file with it, which means that we can disclose important
information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus and information we file later with the SEC will automatically update and supersede this information. Any
statement contained in this prospectus or a previously filed document incorporated by reference will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus or a subsequently
filed document incorporated by reference modifies or replaces that statement. The documents we are incorporating by reference as of their respective dates of filing are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001811063/000095017024023247/nuvb-20231231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2023 filed with the SEC on February&nbsp;29, 2024; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001811063/000095017024059622/nuvb-20240331.htm">March
<U></U>&nbsp;31, 2024</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001811063/000095017024090347/nuvb-20240630.htm">June&nbsp;30, 2024</A> filed with the SEC on May&nbsp;14, 2024 and August&nbsp;5,
2024, respectively; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001811063/000119312524004426/d685245d8k.htm">January
<U></U>&nbsp;8, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001811063/000119312524075908/d785312d8k.htm">March<U></U>&nbsp;
25, 2024</A>, and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001811063/000119312524091875/d824232d8k.htm">April<U></U>&nbsp;10, 2024</A>; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Report on Form <FONT STYLE="white-space:nowrap">8-K/A</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001811063/000119312524164595/d837366d8ka.htm">June
<U></U>&nbsp;20, 2024</A>; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our <A HREF="http://www.sec.gov/Archives/edgar/data/1811063/000119312524188838/d843251ddef14a.htm">Definitive Proxy
 Statement</A> filed with the SEC on July&nbsp;30, 2024; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of securities set forth in the section titled &#147;Form 10 Information &#151; Description of the
Company&#146;s Securities&#148; in our Current Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1811063/000119312521041929/d859861d8k.htm">Form <FONT STYLE="white-space:nowrap">8-K</FONT></A> filed with the SEC on February&nbsp;12, 2021,
and any amendment or report filed with the SEC for the purpose of updating such description. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All documents we
subsequently file pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act, prior to the termination of this offering, including all such documents we may file after the date of this post-effective amendment to the registration
statement and prior to the effectiveness of this post-effective amendment to the registration statement. These documents include periodic reports, such as Annual Reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Reports on Form
<FONT STYLE="white-space:nowrap">10-Q</FONT> and Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> as well as proxy statements. We will not, however, incorporate by reference in this prospectus any information furnished to, rather
than filed with, the SEC, will also be incorporated by reference into this prospectus and deemed to be part of this prospectus from the date of the filing of such reports and documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may obtain any of the documents incorporated by reference in this prospectus from the SEC through the SEC&#146;s website at the address
provided under &#147;<I>Where You Can Find More Information</I>.&#148; We will provide to each person to whom a prospectus is delivered a copy of any document incorporated by reference in this prospectus (excluding any exhibits to those documents,
unless the exhibit is specifically incorporated by reference in this document), at no cost, by writing or telephoning us at the following address and phone number: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Nuvation Bio Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1500 Broadway,
Suite 1401 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">New York, New York 10036 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(332) <FONT STYLE="white-space:nowrap">208-6102</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g881368g00q34.jpg" ALT="LOGO" STYLE="width:3.26042in;height:1.03125in;">
 </P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g881368g00q03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g881368g00q03.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_[1:64&AO=&]S:&]P(#,N,  X0DE-! 0
M     "L< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  /0F]Y9"P@365L:7-S
M82!( #A"24T$)0      $(^UR^%L5A4Z_,@=5@.KKSDX0DE-!#H      .4
M   0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $
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M=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M    $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO
M;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG
M:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0
M$ !@     0 ! &     !  $X0DE-!"8       X             /X   #A"
M24T#\@      "@  ________   X0DE-! T       0   !X.$))3009
M   $    'CA"24T#\P      "0           0 X0DE-)Q        H  0
M       !.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9
MF@ &       ! #(    ! %H    &       ! #4    ! "T    &       !
M.$))30/X      !P  #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z     #_____________________________ ^@  #A"24T$"
M$     $   )    "0      X0DE-!!X       0     .$))300:      ,U
M    !@              -P   *P          0
M   !              "L    -P                     !
M             !     !        ;G5L;     (    &8F]U;F1S3V)J8P
M  $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M         $)T;VUL;VYG    -P    !29VAT;&]N9P   *P    &<VQI8V5S
M5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N
M9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L
M:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L
M:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0
M  0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N
M9P   #<     4F=H=&QO;F<   "L     W5R;%1%6%0    !        ;G5L
M;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$585
M  $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585
M  $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D
M969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N
M!V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4
M>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E
M=&QO;F<         #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T
M<V5T;&]N9P      .$))300H       ,     C_P        .$))3001
M   ! 0 X0DE-!!0       0    #.$))300,      PB     0   *     S
M   !X   7Z    P& !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(
M   !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,
M# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.
M#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,
M# S_P  1"  S * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
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ME<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$
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MY5224_522^54DE/U4DOE5))3]5)+Y5224_522^54DE/_V3A"24T$(0
M50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !,
M00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))
M300B      %*34T *@    @ " $2  ,    !  $   $:  4    !    ;@$;
M  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4
MG $[  (    0    L(=I  0    !    P    .P   !@     0   &     !
M061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R-#HP.#HP,B Q-3HS
M.#HU, !";WED+"!-96QI<W-A($@   .@ 0 #     ?__  "@ @ $     0
M *R@ P $     0   #<         !@$#  ,    !  8   $:  4    !   !
M.@$;  4    !   !0@$H  ,    !  (   (!  0    !   !2@("  0    !
M              !(     0   $@    !.$))30/]       (          #_
MX0%217AI9@  34T *@    @ " $2  ,    !  $   $:  4    !    ;@$;
M  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4
MG $[  (    0    L(=I  0    !    P    .P   !@     0   &     !
M061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R-#HP.#HP,B Q-3HS
M.#HU, !";WED+"!-96QI<W-A($@   .@ 0 #     ?__  "@ @ $     0
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M*"@H*"@H_\  $0@ K (: P$B  (1 0,1 ?_$ !P  0 !!0$!
M   ' 0(%!@@#!/_$ $T0  $# P,"! ,#"0,)!0D!  $  @,$!1$&$B$',1,B
M05$R87$4(X$50E*1H;&RP=$D8N$6%S-#8W*"DM((-$1T\24U4X23HK/"XO#_
MQ  ; 0$  P$! 0$              0(#! 4&!__$ #$1  (" 00! P,"!00#
M       ! @,1!!(A,1,%(D$446$R\"-#<<'1%22!L3-2D?_:  P# 0 "$0,1
M #\ ZH)P51SB&Y57=TP".4#/(2N)[!7N<[#=H!SW5&M&>RN=PW\%+(C^2TR$
M.QPDCW- ( 5L>",G]J5#@V)QQNP#P%!,BQL[B< -7R7&[Q40S)(QHQGD%8&_
M5%9.TQ4#YJ>0.!WC(XQVX4>70WE[3]HJ:F48]=Q7135Y'@\W5:UTK"1(-9KF
MD@)#:BF[XY8Y8FHZAU /]G%$\8]6/[_\RC61KW/<V4G<.^Y9W3=EEGK(Q(W+
M"XYW-./A7:])&I9GAGBKU.^V>V/')O\ IW5-VNLTC?LU*6- .6-<.Y^;EMM9
M<*>AIW35LK8HP0"X@^JP5KIZ6TT9>&Q0N#/,1AN['*A?J?KV:[NDI[7+501N
M:P[0\8R"<]ES*CRR]BPCZ33N6WWODEZRZ\MM?<JVEDK*<>',(HMK' NRXCG]
M06WNE:(]^1M]UQM!/<;9/2UADJ 9'-E<X9!."#G/XJ>NG>N8;M0P05;Y#*[>
M2Z60>A/S5;J-K]IT?&21);E!'(QCI&ASC@#!Y7T,J&/&&.!=[+4]0TLLM+)/
M32ACF1N<PCOGN,+2*+5%9;*U\=9-4REK<'S>IP?54C3N7!YUFOC3+$T2^:DC
MXMH5\<SGGL,+3K-J.*Y$?$SS;?.X+9:>88&'9X]"J.MH[*]55:LQ/MDE+3AN
M"O5A):">Y"L:&N!. #\UZ#@!989J$1%("(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( 515
M)5I]T)*@JV1Y;C';U7G).R)I=(YK6#NYQP%\L=='4.>(]K@WU#LY5E%LI*21
MC;]JZR625T-TK#"\ $@1/=W[=@5B6=2])-<&MNCLN[?V>7_I46]=G.-\E+92
MT>'%Y<_5:I8M*7"^QNEIG3L\#;G;$YV[/T^BWC5QR91DVSH'_.1ID/.^XD,]
M#]GD_P"E9*"\6J[1NAI*ES]_E^!S?WA0 _I[>0=YGK,'C::=_P#582BNMZT[
M=J::M=<HHV.WF.1[XP\=O5:K3K9OCV++%'VLGR[:*HJFJDG<^IW//.'MQV^B
MSE0Z*PVZ6JJ7%E)&07O/F(R0T<#GOA8/1FKZ&ZV2EFJZB"G<YA<?&J&DYW$8
MYPH@ZBZ\J]0UC::WBKCIWPM:Z**H+FN<'%V2!P3V_4J5PML>)+HRA"O.Y'V]
M1^H/Y2JS1T+H)(HY7-:3$\'!XYR53ICT[GN$\<]QBFCHLO:Y\<K,@XXXY/[%
M'IIZBFDBJ:RDFVN<'9E81NQSW(71/3/6%NN=O#(8:>E>9'XA$K<\ <XP%O9N
MKCMB=6RI+LR-]T+25UE;3;JG-/3NCAQ(T%WEP,Y'R'LN=[]:*S25VD@?%M$;
M1\;@\^89_-*ZY%3&8MQV[=N<YX 4 ]:JVCFNM6R)D$C\1'Q&EISP%A19L;W&
M;Q'B/R23HJ\#4%D::4MD-/&R-^&EN#M^:U77MMDBGFJ)&D!TC1\0_1_P7T=!
M&.9:KEEY(,L9Q_PE21<;3!7L_M#82TD'[Q@=^]3&Z,)O'1QZOT_ZBO#R0/35
M!B>'T>'[3^</7]BW+3>KQ"X15SHH]K,>6-QYS^*W)^EJ"/X(:,?2!H5L6FJ$
M/)^STA/OX#5,[HR.#3>G3T\LQ;,]1U<-:POIG[P#M[$<_BLBSX!GOA8RW4;:
M8>1S0,YP!CT609(QV0US7$=P#V7&VF^#Z%/VH]$5C7Y;G!"ORH&0B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B M<TEP(7SU$SV#C'=>[SMY] M:U/<8Z"G=(][1O) !=CG
M"O!99E?9XX;F8#7>H_L\$]!&[[YS6. +./BSW_!?7H6>22%YEQYHXSP/JHKJ
M:A]=4^-(7!^,;2<J4="O!@#> 1'&/V+K<,09XNGUOGM2(QZ\QDWN4M[^'%_-
M;OT.>\4->'X[0C]CEH_79KAJ64C)'A1?S7GH'7T5EBG:Z"$[MGQ3[>V?DK..
MZO"/;C#:LG1CF%Y(/PJ$.N]LB>^G=*'>(*<[<'CXE]TO62%KCBDIS_\ -_\
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MP/;:?FLXPW/!UVZA5P\CZ-X$A(SDJR9WE;]5'&E[E5UUHJW-CC,K7X:T9 /
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MC#G%XVDGO]5-_0:>"/1OV4RCQS4R.#/7&&K7M9=* UCI;8VA@@:7.9&-V6M
MX'91UHK4]=I>YQRU,M2:1H=F*/ ))&,\X7-9/?7A$QCM.L:F:.GI7S2/#6QL
M+R3[ 94&]4NI#9:>HH;2*>I=NC<-KW9/J5C=9]39[M0TD5IEK:4&-[)PXM^\
MW  =B?G^M:II;2%?J"M9.V6)H>UW,H=Z<>@5:JU6TYEMV>C':4ML=QU+;VNE
M=NGJX]P'.TN<./VKJBQ6B*WVJ"D+ X1Y\SFC)RXG^:Y4L=4ZPZGBGG#RVCK
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D (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g881368g00q34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g881368g00q34.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_[2.R4&AO=&]S:&]P(#,N,  X0DE-! 0
M     "L< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  /0F]Y9"P@365L:7-S
M82!( #A"24T$)0      $(^UR^%L5A4Z_,@=5@.KKSDX0DE-!#H      .4
M   0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $
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M=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M    $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO
M;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG
M:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0
M$ !@     0 ! &     !  $X0DE-!"8       X             /X   #A"
M24T#\@      "@  ________   X0DE-! T       0   !X.$))3009
M   $    'CA"24T#\P      "0           0 X0DE-)Q        H  0
M       !.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9
MF@ &       ! #(    ! %H    &       ! #4    ! "T    &       !
M.$))30/X      !P  #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z     #_____________________________ ^@  #A"24T$"
M$     $   )    "0      X0DE-!!X       0     .$))300:      ,U
M    !@              8P   3D          0
M   !              $Y    8P                     !
M             !     !        ;G5L;     (    &8F]U;F1S3V)J8P
M  $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M         $)T;VUL;VYG    8P    !29VAT;&]N9P   3D    &<VQI8V5S
M5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N
M9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L
M:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L
M:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0
M  0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N
M9P   &,     4F=H=&QO;F<   $Y     W5R;%1%6%0    !        ;G5L
M;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$585
M  $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585
M  $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D
M969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N
M!V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4
M>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E
M=&QO;F<         #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T
M<V5T;&]N9P      .$))300H       ,     C_P        .$))3001
M   ! 0 X0DE-!!0       0    #.$))300,     !D^     0   *     S
M   !X   7Z   !DB !@  ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"
M$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#('-2
M1T(               $  /;6  $     TRU(4" @
M                                           18W!R=    5     S
M9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA96@   A@
M   49UA96@   BP    48EA96@   D     49&UN9    E0   !P9&UD9
M L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4;65A
M<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P   @,
M8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T
M="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C8M
M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                 %A96B
M  #S40 !     1;,6%E:(                     !865H@        ;Z(
M #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@   /A
MML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                9&5S8P         N245#(#8Q.38V
M+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M   N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S
M4D="                             &1E<V,         +%)E9F5R96YC
M92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                                  !V:65W       3I/X %%\N !#/
M%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,
M     0                        */     G-I9R      0U)4(&-U<G8
M       $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9
M %X 8P!H &T <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +< O #! ,8
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M# P,# P,# P,# P,# S_P  1"  S * # 2(  A$! Q$!_]T !  *_\0!/P
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M[2ZC-V,RF-$P]CA93<&M_?V[/_.T=V4WIW6NI#(KL/VQM9QMC'/WEK2QS&[
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M]6Z*VW5/):X$.;776Z=W\I$PB-O'_P!)[?XRT9\DB"3H3"-;7_2/;,XRA/\
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MJ27RJDDI^JDE\JI)*?_9.$))300A      !5     0$    / $$ 9 !O &(
M90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T
M &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      4I-30 J    "  (
M 1(  P    $  0   1H !0    $   !N 1L !0    $   !V 2@  P    $
M @   3$  @   !X   !^ 3(  @   !0   "< 3L  @   !    "PAVD !
M  $   #     [    &     !    8     %!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*0 R,#(T.C X.C R(#$U.C,Y.C$Q $)O>60L($UE;&ES<V$@
M2    Z !  ,    !__\  * "  0    !   !.: #  0    !    8P
M   & 0,  P    $ !@   1H !0    $   $Z 1L !0    $   %" 2@  P
M  $  @   @$ !     $   %* @( !     $              $@    !
M2     $X0DE- _T       @          /_A 5)%>&EF  !-30 J    "  (
M 1(  P    $  0   1H !0    $   !N 1L !0    $   !V 2@  P    $
M @   3$  @   !X   !^ 3(  @   !0   "< 3L  @   !    "PAVD !
M  $   #     [    &     !    8     %!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*0 R,#(T.C X.C R(#$U.C,Y.C$Q $)O>60L($UE;&ES<V$@
M2    Z !  ,    !__\  * "  0    !   !.: #  0    !    8P
M   & 0,  P    $ !@   1H !0    $   $Z 1L !0    $   %" 2@  P
M  $  @   @$ !     $   %* @( !     $              $@    !
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M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" $U ](# 2(
M A$! Q$!_\0 '  !  $% 0$               <" P4&" $$_\0 5!   0,"
M! ,$! <)#08' 0$  0 " P01!082(0<Q01,B46$4,G'1%2.!D:&RP20S0E)B
M<G.QT@@6%R4T0U-C@I*BX? F-723L\(V1&2#A)3Q5$7_Q  ; 0$  @,! 0
M             P0! @4&!__$ #,1  (" @(" 0($!@$$ P$    ! @,$$1(A
M!3$3(D$&,E&Q%"-A<8'!H15"D=$D,_!2_]H # ,!  (1 Q$ /P#JE$1 $1$
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MTN YE>-'542+!ALJ,C?%>!P)V*MV\U4P;A9T:J3+R(BP;!$1 $1$ 1$0!$1
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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ME^:%RM-:=I>W=@V)74_"ANC+&&^!H8;?W0I<^*4.BK0]R-VC)+=U4T6OYKP
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 6Y'-:[<B]N2UK.^+MP_#
MH]+FWE)8>_:VQ6P5<;G'4P@. VNHWS4R7&JST&-S=5/,2[7L".6Q"WK6GR(;
M)M=)&D4&$U-?5,CIXY9&.OWV,+N0NMWP/*#H]YX7$V:>_"MIR_@$.$P-#6-$
MK7$@M>XC?VK/12-O8WOR5NS-E):UHY=?BJ^?R3]F'P_!X:=MC2QGGSB 64IZ
M>*,.TP1M/2S0%;Q7$8\-B,TX>8P0+, )W6B5_&# *230ZGQ/5<BXB81<?VU6
M4)S](ZL*H5^B16Z@=VFRCOC:X-RW6$ $^C_]P5NDXP8-52%K(<1&U]X6?M+%
M<4\PT6*Y<K13QS@]CI[[0/PAX%34TR5B4D;RFFNCGYKRYQ-K*>OW.A+\!G<Z
M/<5T@N?T3% \);K<' V4]_N=W$8#/I]3TZ2X_P#:8KV6N->B&#VR96EAO8-U
M#F%\.*893XK2NAJ(H@XD&[HPX[>U?:UK&DO W=S5=M[]5QTVNRQHYOXE</JJ
MCJW5=!!/+"UTTKQ'3V: #<7MTYJ,NT='(9"#&[EV-[6796/QQOPJL]):71=A
M)J .Y;I-UR5G2GI8\P5$F'QNCH[,#6.)+@=(OU/7S75P;I3WR7HKV17L]J\Q
MXC649@FJ:ID/9]F6&=Q:6V\/!8B&&:8:*6)\CAOW!<V7H8[072D%@%R!X+8L
M@5^$TF,2/Q.GGEI>P<&MCYAVIN_,>:N63U'I&(OO1,'##AXS"VMJ\0OZ1'.7
MM9-3@$C2.1)Y<UO&9,L4&-TK(9H*>,,=J!,#77-B%F:::.IA[6,.&G875YG?
M];>VZX4K)-[+'%:(XI>%F'11.:\P&YO<TC?>H[XP8'1X/2T#*6&!KM<C"YD0
M838#?9=&N<T@\U"G'7#)IJ:DD8Z, 23.W)Y6'DK&-:W/4GT13CUT047%M.3O
M(Z_JE=<Y6P7#O@/#Y'8?2%[J:)Q)@;>^D>2Y'I;"H$<N[K7V79&6':\#P]K>
M0IHAO^:%)E3_ $8A!GTLPZA#C:EI@/#LF^Y1GQNP9DV'&>DA:WLJ=U^SC'/5
MY*5;6D+>JQ^+X92XM134U5'K8]N@C46[?(J<)M/9L<;]I+1[LFD;+R< X@J4
M,E\3*K!V=G6!]4#(7ZIJIVPT@6W!\%\?%#(\6#UDE12QQ,@DE:QH[1[B.Y?>
M_L4=ZA+=@O<^*ZT(JZ'&7HQ*7&.U[-ISKG:LS!BE01VM/ )7.9IG<YI!\.2U
MBGII*NK92T@=)*^^GLQ<[ D_0%1 T=H]DHN&\K*7N#>6L)K9Z6LJ*8OJ6RR-
M#^T<-M!Z VZE9<8T+:^Q"MS(\QO+5?@]+035-/4 53"\&2(MY $V\?66';JA
ME[1KW7Y6!LNJLXY4AQG"71SQL>:2"1M+>1S=%V[7MS]5O._)<PXWA\N%5[Z"
MJ+'5; '%T9);8B_6WZE''-E-:T'#1,?#/B5"(!28K)%!9T<3'3U/2UK@$*46
M9EP6=H+<6HC??:9I^U<>-:X3Q.:1J:00?E60^&\0IG&.&<-+?R&G[%AX,;%R
MV;1F_3.DLR\0<*H\,J#1UU'/,&$M:RH )-^6RYRS3F";'<8JGRE[6NDUAID+
MP-K+&/=532!XD;H'K C<_0K4KJ>1PCIF.;5ZOC'N]4^S?V=%+7CUT][-++I)
MZBMF4P&AEJ<;IL/AA=*Z:Y%FW.S2>7R+K')U)Z#E_#89!H>REC86D6((:-E%
MG"#(TL=9'BN)^CRU-/,]K'LD=LTQVM:P'X14SQLM<=&<ESLN[Y'I%NJ*4=L^
M;&)NQB<XFP%M[VZJ#\=J!-C%7(QUW13R.%C??4?<I0SYBK*;#I0W6'=PW !Z
MJ'97ZJFHE;_//+CYW)/VJS@UOB]GE?.Y2A.*C]B5>&V)"HPZ*%\GQPUDL+[N
MMJ6]17ZW4+\/Z\4>+W.JW9.&P!ZA35"=<,;A^$T%4\BMU,Z_BLG^*JYOIE37
M-#B"X75Q?,YGQCBKY.RK)[.HD>D@<RO+@[C=4N&H;(P6"/UL??17J'B$+VM&
M[@/:K;HS>XMXJB2-TL9L1\JRA+I=%WM8_P =OSIVT=O7;\ZQU4UT--*\D=UA
M.WD%'&+YSGH\4FIFRR!C+6 C:>;0?M4U53M>D5K<A5+<B5O28+V[5E_:JQ(P
MC9[?G4.T.<I)*J-KWRD%W]&U21@=4*ZDC<+W+=6XMU2VEU],BQ<Z&3+C$S@(
M/(W2X\5;@V:;^*<W.4)?UV7+CQ5N2HAC^^2,;[2O/5W*CO.N8W454QC7/%GO
M&S&GD0LT1=LN)6R\B.-6[']B0A5TYY31G^TKHD8;6<-_-0]A>:WS5&DODY'\
M!JDZB<9:>GDOS8UQO[%-=0ZO9'@YD<O>OL94$'D45J,W<1Y*Z% 7%V>7'B%Z
MK3FG42KG0IM!'J*EO5>H!<>(0N %R0 J-)U?*DS2]FD<UC?9@J#VGDX*H;\E
M\T4+@=R%]#18660F_N X'D0O20.95IC"' [*I[2[DAE=^RL$'D0EU0UA Z)?
M= 5I<>*\&Z\TE#)4EQXKP;#=4#FAJRXO+@=4OLK<G(H;+^I=!!Y%%\[)&MVL
M;\E?;R0QM?8]2X\5\T]2R,C4'?(K8JXW'8.^99XLQRC]V?:A('->-W;?Q"I>
M1:SMU@R>ND8WUG >TJGMXOZ1OSK2L^8_+ADD3:=[FET>KU >OFM.9G>M(LZ=
MY/Z)BLU8T[([1SK_ "=-$W";)H;(QPNUP(\E[J'B%KV4L0=6T3^T)<_M2 2
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M'==!<,,_G%Z>.CK!42U,4&I\CM-G'4!?;VJ/+E+?1BE)^R38XHV1D1-:!?\
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M5SRB=^HJ",TD-QRJ&Q]7ZH4\8@/XMJOT3OU%0'FD_P ?55_R?JA=+QT=S?\
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MD/RJ0N$F.08*9NTC:;SQN]<-Y+I6QE*/16C[.FS8,LJ7-(!TBY6D_P (E"6
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M1.CLW1I<;WW)O]*NX54JY_4<+S.33DU\:NF?7E^41XD)&'[XYO/VJ=!%^,%
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M="%SP-,QN\G:W@M=SME>@S#ASF5L':RQM>Z'XQS;/(V.Q6P02/>TNDCT.!L
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M3 &]X3]91W(;1M78PY:K1X/RTU'*FF35D0$X1,?Z\_5:M'XC?%UUSUE>M[R
M+X1,/&<_5:M7XMTG9"BDOZ\K^GL7/IZN/2>8K<\*7#^G[HCU\@<VZGO*+@[
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M8[1/Z!_O7664) [+6'O'X40_6N1*)XIYF2.([IOOLNI.%^*0UN5L/B8]A?'
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M"LVS<.(_$?$(L2=3X'5U5+V,SA)J8RQ;X#FM-QS/=;CN$ST<M34/;+I!#V-
M-G!W3V+37N<^34T7D>>\WP4H<,L@25]935\@J&PL?(PN;IL.X?>IOAA4MC>V
M9+A1D03 U^)LI9P[L)Z>SW79>[M]AOZOCR4]4\09"&&UO)4X? *2@IJ<$D0Q
M-C!/,V "OO%PN;;:YOLL+UHB#CK1E\$;SI.FFE(W7/P/Q(B/1='<;WEM$T6Y
MTDJYO+7!Y>T7)70Q$W'HKSZD37P-S7#&^7#J@5#Y:F=H80UND=WKO=3J&AS>
M6W1<7T=:ZAJHJZ(-?)3G4&NY'VJ1,L\6ZJE%IZ6C8!'8$Z_'VJ/)QMO:-E,Z
M)8UP8=9N[H5IO$/.=+EN@;VK:KM9=<;'1,:;. YFY&RC/$^,U8^DD]#HZ&62
MPLWO[[^U1AB^)R8A5S5I8T3U,CI9F-O:,N-R!\ZBJQ^^QR/IS-C59CU7\(5\
M[YHPP1D/ #MKVY>U?!2T\M;4TE-&YH=,]L<6KDTN( O\X3#<+DQ2H#<.:^>I
M-],;;"X'/FN@.$N1GX-!Z77=O%-,V"4,=I(U $D;>95UW1KB:\=GS\+.'L='
M#'58M%2SU!:]KGL>_?O;= I?B8V.)L;19C0&@>05!U= O6@]5R+;7+MDL47/
M(+U6_55Q1Q>S8(>2(M@?.39Y]JK>26FQ7A!)=9(AWUK6M;,;TRQB6V&U)_JG
M?J*@3,^^8*IPY'3]4*?<389**=@ZQN'T*$LRX%7R8W4NAIWN8=-C<?BA=' L
MX29PO.4.Z,=?K_[*\I6&-48:+ RBZFJE ,# >5E$.4<(K8,7I7R4[@!(#N0I
MBI=0C&L6-E'EV<Y&_A:736]_J5-L>BL54+)6/#V@BQ5][NI5LF_)4XMJ1VVE
M-:(AX@X08Y75%((XW-C: ;F_K%:DUCG1- ([1H[Y\2IVQRA-=3/C:';VY>14
M08MEFNCQ*K[.GD<UTKK$D<KKK8M^FMGE/)>-Y)N/['P4,3FR:@1JL1=3Y@Q<
M<(IKG?L&?54)8?E^N8^[J>0;'J%-N#,?'AL#'ML1$P?0H<ZQ3D3> HE2Y)HT
M_B5AC*G#F2-:SMC4-U.).XT.'N42M[[G1.W)-O)=%UD)>SD>:BC,.4:QL_I$
M,,KPP%W-MN94F)<E#@S'GL*RR7RUK_PC#X-C]3A'Q)FD$+6Z6M8T&V]^JVT9
M_:[NZJNY_(9[UHDL=:R1T4M/IT^:I?05DTH;# 7.(V%PIYPA+MG-JORZ8\8Q
ME_R9;&LR5&*2RQF:4QL<2T/:T6^9:_&^('OM)=XK;,*RAB#Z<R/II6ET=[7:
ML-5X-BU+5:(J%SP!>Y(]ZQ7."Z17R:LNR*E)/O\ NS)9"N[$GD'82QV_O%37
M!_)F^W[5$>3,(Q%N(,DGI', DC<=QX[]5,$8(B *K9\XR:T>H\+1.FKZT_\
M*T> #21T/-1KQ.P^,-,\#&LF=,P.=<[C0?<%)F]PL-F.A=60!H#MI [;V%5:
M)\9EW/I5U3B0.Z!Q>+D%O4+V"%\M2R-A :UPV/M7VMR[B/9/O32?.%G,G9<K
M&UKWR0R-%@>8\5VK,E<7_P"SQ%?C)NU>_P#P25E*E91X:\!H![4G;V!9>9PT
MCS7D<9$1:1O=5M ( ON%YVZ6Y'T"B"KK431L_P!!V^&O# T=YO,E14S2'SQ/
M%WM):T] =PNB\0@%33F.YY@[**,U9-G9.^>%DS[E[^;?&Z[&%E0C'C+1Y[RG
MCN<OEC^Q\N5\RR8- RGDDFTL:X6C:TC=U^JV+^$"B L&5FH]=#>?]Y1X^@JX
M!:2%S3[0C&32M+&QW<=@ M;W7.6^CFX_D<BB+K47U_<WNMSHZ:$>CR5#1JON
MQO+?S4>M<^4:WNNX;766PW*5;6/+C!*&EMP06^*OY@RM6T=8R*""61IC#KN(
MYW/N4M<JX+4=;-,N.3E5\YIZ_3LQF$_[PA\>T;^M=!N%FFR@_!L#KHZN)SZ=
MXLYIYCQ4Y1..GOBQ5;-DGQ9W?"T.JIID:<5X0Z&B<T $.D-_F4<M8Y])<D%U
M^:G3-^%_"M%H:7ZF-?8-MO<>:B&NRM7TLIM3REMAN2%/BW1^-(YWF<%SLYI?
M\&4P?.$U'&622SFP:!I:W:RD'*N/_"E.QY=*26N/> ')UNBAN?#ZH.:#"Z_+
MF%)?#*EFAIXS)&6CLWC?\]59J+BV3^,NN5D83WHQ_%@%V(T3>AA/UBH_GA[@
MM;FI'XGX=55E53N@A<_3$1L1^,M!CP'$M9U4CP/:/>I<>S4$MG.\UB2ED2DD
MWO\ H2QP[D/P-,7$D^D.^JU>YUPEV*4\1D[-S8RYS0XD6V\O8KV2H)*>@DCD
M:6DS$[_FA;+I<6.%N855SX6<D>JJK5N-PD<X5L+H:OLY"#W;[+*8;BU7A;F/
MAG<R*[7/:T D@>WY5O6<LK35VM\+)7.LT6%EH$F7:^BD>7TT@ )M<C>RZ,;8
MV(\K/"LQ;7*._P#"-QI^(M*Z,!S:TN_,9^TL%C6::O$0Z.">5L+VEKFO:T7!
M6"?%4:CJBLKK<.K*JS8H'.OML0L*JM/:-\C(R+8<5O\ Y/E<UT??)&H[$A;U
MPZP(LJ(IZH12/;,;$$[#2/)?!@>2ZB4-=4,GCNT\BWQ4MT5/V5.1OS4>1>HQ
MXHL^(\<^?R6?\HIJX6MAEV%M)M\R@K%X2:MEK>H/UE3O)&YT<UAS:5".-8!7
MNK&%M.\]P=1XE5*+'%[+7GZFZTHK?]AER,LQ6DTV'QT=_P"\IV<2#L=E".6,
M#K8<3A?) ]H$K#S'XRFQMSS6V4^31M^'ZY0KGR6BH.+F/WZ+0>)USA(%_P">
M9]4K?F#2'+4>(5+-584&Q,+OCFG;V%14/4CIY\.=342'RTF&0[:AR*D_A8VU
M(POW/8GZZCIV7\2U.M2/L3XCWJ4.'%%44E%&V>(L(B(W_.5S(FG!GFO"8\H6
M[DM?X-UC>US26@BQMNK@Y*D<E4!LN8SV!Z%'O& D84SP[&>_]T*0EHW%6EK*
MK#(V44!F/8SAUCRNT64V.]31K/M'*6IO8]P$.OS6>ROCM9@>MU%.^$N>UYT
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M &J]DVM1/.>+Q9SN7+TC:,-I8L/:((HPU@N>[RW5W%<1AP^BFJ)2 V-A?;4
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M>]L?)<BU/TBU%IHB_C>0:(>/HLJYS#BPW<"6^"Z*XVL/H@<\6#:64_(N=V5
M>\L!&D;@V7?P&E5I^RO:N]GU0X?458[2G8\PLV> TFZ^:HII(9"WT64 &WJ%
M3GP"@958)B\,I<&OG:#IY^JI K<FX;5C3)+5  W[KV_LJ&[,A5)QF:QKE);1
MR:V-T<@:RCF-]^ZPK(X'@-;B]=V,,,L(<YH)?&ZQ!-O!=04&2\,I7"1DM5L>
MKV^'YJSM+1QT8^(+B" .\>BBEF0:^DEC5(C_ (?\-J?+[V5%6VFGF:YW>8'
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M.T %[%?2&@-MTM96S TMM<V1R;$(Q@FD6VRM<;6*M5L<4L6B5FMM[V7T-IV
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MN+BA@_Z;5G!SW-ES5A?%FHP[#:2F9-4CL861BT$9'= '5??#QFK)!<U%3_\
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MRR_<R#L%I-1)#[N-_65PX1 V#3&'7OU<OGBS#AKK 5M(\FW\^TV^E9."JBJ
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B *F2-LC2UXN"B(#YL/PVEP^,LHXNS:7:B
M-1.]K=3Y+ZM(O>R(GL%$T,<S-$C;M\+K NR5@#I'O=A]W/.IQ[:3<_WD1;1G
M*/Y7HCLIKM_/%/\ NMEV+*."1?>Z*W_NO_:7WP8310?>H=/]MQ^U$679)^V8
MA15#\L4O\'UQQ,C%F"P]JK1%H2^@B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
7( B(@"(B (B( B(@"(B (B( B(@/_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
